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Abstract 
With the evolution of cationic liposomes into one of the most appealing and 
versatile nonviral vectors for the delivery of nucleic acids and the discovery of RNA 
interference (RNAi), the development of devices to deliver RNAi molecules to specific 
cells as became an appealing strategy to achieve the treatment of genetic disorders.     
Hence, with this work we intended to develop and characterize novel systems 
for therapeutic siRNA delivery based on dioctadecyldimethylammonium chloride 
(DODAC)/ monoolein (MO) liposomes, which previous studies developed by our group 
have validated as a promising system for plasmid DNA delivery, These systems 
demonstrated to have promising features compatible with stable and efficient 
encapsulation of RNA. Furthermore, DODAC/MO vesicles were coated with 
polyetilenoglycol (PEG) and PEG-folate grafted lipids to increase circulating half-life 
and obtain selectivity towards folate receptor expressing (FR+) cells (an overexpressed 
receptor characteristic of several cancer cells including chronic myeloid leukemia). 
As a result of this project, DODAC/MO/PEG liposomes and derived RNA-
containing lipoplexes showing stability in solutions of different concentrations of salt 
and H3O
+ and in fetal bovine serum solutions at 30 e 80% (v/v) were produced. 
Additionally, it was possible to observe that the liposomes and lipoplexes coated with 
PEG-Folate are better internalized by FR+ cells than those with PEG only. 
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Resumo 
Com a evolução dos lipossomas catiónicos para um dos vetores não virais mais 
apelativos e versáteis para a entrega de ácidos nucleicos e a descoberta do RNA de 
interferência (RNAi), o desenvolvimento de dispositivos para entrega de  moléculas de 
RNAi a células específicas tornou-se numa estratégia atrativa para alcançar o 
tratamento de doenças foro genético. 
Assim, com este trabalho pretendeu-se desenvolver e caracterizar novos 
sistemas para a entrega de siRNA terapêutico baseados em lipossomas de cloreto de 
dioctadecildimetilamónio (DODAC)/monoleína (MO), que haviam já sido validados 
como sistemas promissores para a entraga de DNA plasmídico, em estudos 
anteriormente desenvolvidos pelo nosso grupo. Estes sistemas demonstraram ter 
características promissoras compatíveis com o encapsulamento eficiente e estável de 
RNA. Adicionalmente, os vesiculos de DODAC/MO foram revestidos com 
polietilenoglicol (PEG) e de lípidos PEG funcionalizados com folato para aumentar a 
tempo de circulação e obter selectividade para células expressando receptores de 
folato (FR +) (um receptor sobre-expresso em muitos tipos de células cancerigenas, nas 
quais se incluem as de leucemia mielóide crónica). 
Como resultado deste projeto produziram-se lipossomas DODAC/MO/PEG e os 
seus respetivos lipoplexos de RNA mostrando estabilidade em soluções de diferentes 
concentrações de sal e H3O
+ e em soluções de soro fetal de bovino a 30 e 80% (v/v). 
Além disso, foi possível observar que os lipossomas e os lipoplexos revestidos com 
PEG-folato internalizam melhor nas células FR +, comparativamente com os sistmas 
contendo apenas PEG. 
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DODAB - Dioctadecyldimethylammonium bromide 
 
DODAC - Dioctadecyldimethylammonium chloride 
 
DODAX - Dioctadecyldimethylammonium chloride or bromide 
 
DOPE - Dioleyl-phosphatidyl-ethanolamine 
 
DOTAP - 1,2-dioleoyl-3-trimethylammonium-propane 
 
FBS - Fetal Bovine Serum 
 
LDH - Lactate dehydrogenase 
 
MO - 1-monooleoyl-rac-glycerol (monoolein) 
 
mRNA - messenger ribonucleic acid 
 
MTT - (3,(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)) 
 
xii 
 
NADH - Nicotinamide adenine dinucleotide 
 
PDI - Polydispersity  
 
PEG (PEG (2000)-PE) - 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] 
 
PEG-Folate (DSPE-PEG(2000)-Folate) - 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[folate(polyethylene glycol)-2000]  
 
RNA - Ribonucleic acid  
 
RNAi - Ribonucleic acid interference 
 
Rhodamine B DHPE - Lissamine Rhodamine B 1,2-Dihexadecanoyl-sn-Glycero-3-
Phosphoethanolamine Triethylammonium Salt  
 
siRNA - Small interfering ribonucleic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Index 
Acknowledgments ................................................................................................................................. v 
Abstract ............................................................................................................................................... vii 
Resumo ................................................................................................................................................. ix 
Abbreviations ....................................................................................................................................... xi 
I. Introduction ........................................................................................................................................ 1 
1. Gene therapy ........................................................................................................................................ 1 
2. Cationic liposomes are promising vectors for gene therapy ................................................................ 1 
3. Cellular barriers dictate transfection efficiency ................................................................................... 8 
4. Gene silencing through regulatory small RNA delivery as a promising therapeutic tool ................... 10 
5. Chronic myeloid leukemia .................................................................................................................. 13 
6. Objective ............................................................................................................................................ 15 
II. Materials and Methods .................................................................................................................... 17 
A. Materials ............................................................................................................................................ 17 
B. Methods ............................................................................................................................................. 18 
1. Liposomes preparation ....................................................................................................................... 18 
1.1 Lipid film hydration .......................................................................................................................... 18 
1.2 DODAC/MO (2:1) liposomes with 1, 2 and 5% PEG (1mM) .............................................................. 19 
2. Lipoplexes preparation ....................................................................................................................... 19 
3. Light interactions with matter............................................................................................................ 20 
3.1 Absorption ........................................................................................................................................ 21 
3.2 Fluorescence ..................................................................................................................................... 23 
3.3 Dynamic light scattering .................................................................................................................. 25 
3.3.1 Size ................................................................................................................................................ 25 
3.3.2 ζ-potential ..................................................................................................................................... 26 
4. Liposome stability............................................................................................................................... 28 
5. Complexation assays .......................................................................................................................... 29 
6. Encapsulation efficiency ..................................................................................................................... 30 
7. Lipoplexes stability ............................................................................................................................. 30 
8. Destabilization of lipoplexes ............................................................................................................... 31 
9. Cytotoxicity assays ............................................................................................................................. 32 
9.1 LDH (Lactate dehydrogenase) assay ................................................................................................ 32 
9.2 MTT assay ........................................................................................................................................ 32 
  
 
9.3 Liposomes toxicity ............................................................................................................................ 32 
9.4 Lipoplex toxicity ................................................................................................................................ 34 
10. Internalization assay ........................................................................................................................ 35 
10.1 Internalization assay statistics ....................................................................................................... 37 
III. Results and Discussion .................................................................................................................... 39 
1. Characterization of liposomes DODAC/MO (2:1) at different PEG percentages ................................ 39 
1.1 Liposomal mean sizes ....................................................................................................................... 40 
1.2 ζ-potential of the liposomes ............................................................................................................. 41 
2. Cytotoxicity of liposomes DODAC/MO (2:1) at different PEG percentages in L929 cell line .............. 42 
3. Stability of Liposomes DODAC/MO (2:1) and DODAC/MO (2:1) 5% PEG ........................................... 44 
3.1 Effect of NaCl concentration on the mean size and ζ-potential ....................................................... 44 
3.2 Stability in fetal bovine serum .......................................................................................................... 46 
3.3 Stability in different pH .................................................................................................................... 49 
4. Dynamics of RNA complexation ......................................................................................................... 50 
4.1 Dynamic Light scattering studies. .................................................................................................... 50 
4.2 RiboGreen assay ............................................................................................................................... 53 
5. RNA encapsulation efficiency of both lipoplexes at charge ratio 10 .................................................. 55 
6. Stability of Lipoplexes DODAC/MO (2:1) 5% PEG – RNA Charge ratio 10 .......................................... 57 
6.1 Stability of lipoplexes with increasing NaCl concentration and incubation time ............................. 57 
6.2 Stability in fetal bovine serum .......................................................................................................... 59 
6.3 Stability in different pH .................................................................................................................... 61 
6.4 Destabilization with Heparin ............................................................................................................ 62 
7. Toxicity of lipoplexes DODAC/MO (2:1) 5% PEG (0,5 mM)- RNA (10 μg/mL) C. R. 10 in L929 and 
MDA-MB-468 cell Lines. ......................................................................................................................... 64 
7.1 Toxicity of lipoplexes DODAC/MO (2:1) 5% PEG (0,5 mM)- RNA (10 μg/mL) C. R. 10 in L929 cell 
Line. ........................................................................................................................................................ 64 
7.2 Toxicity of lipoplexes DODAC/MO (2:1) 5% PEG (0,5 mM)- RNA (10 μg/mL) C. R. 10 in MDA-MB-
468 cell Line. ........................................................................................................................................... 66 
8. Internalization Assays ........................................................................................................................ 67 
IV. Conclusion and future work ............................................................................................................ 71 
V. Bibliography .................................................................................................................................... 73 
Appendix 1........................................................................................................................................... 79 
Appendix 2........................................................................................................................................... 81 
Appendix 3........................................................................................................................................... 85 
Introduction 
1 
 
I. Introduction 
 
1. Gene therapy 
Gene therapy is the attempt to correct genetic disorders, utilizing genetic 
material designed to correct the anomaly. In spite of  holding  great promise in the 
treatment of hard-to-cure human diseases, the expression of therapeutic nucleic acids 
in cells if far from being a simple endeavor, as the human body has evolved to protect 
itself from environmental aggression, such as the incorporation of foreign genetic 
material [1]. 
 
2. Cationic liposomes are promising vectors for gene therapy 
Application of naked DNA in gene therapy is rather inefficient, since the DNA 
molecules, large and hydrophilic due to the negatively charged phosphate groups, [2] 
are prone to degradation by serum nucleases [3, 4] and clearance through the 
mononuclear phagocyte system [4] Complexation of DNA mediated by electrostatic 
interactions between the negatively charged phosphate backbone of DNA and cationic 
molecules leads to charge neutralization and compaction of the nucleotidic fragment 
[2]. In the case of the application of naked RNA the molecules cannot cross the cell 
membrane, due to electrostatic repulsion between their negative charges and are 
rapidly cleared by the renal system [5] having very short half-life in blood [6].    
One solution appeared in the employment of viruses, one organism that has 
specialized in the infection of host cells to express its own genetic material. This 
capability makes them obvious candidates for the use as vectors in gene therapy 
assays [1, 7].  Nevertheless, despite their efficient mechanisms of gene transfer, the 
application of viruses in gene therapy involves several drawbacks. The production of 
therapeutic viruses is difficult, the repeated administration leads to acute 
inflammatory responses and there is a risk of insertional mutagenesis associated to the 
integration of foreign DNA by some viruses [3]. Aditionally, the limited size of the 
carried transgene [8], the possibility of endogenous virus recombination and the 
oncogenic effects [4] impair the application of the virus in gene therapy experiments. 
Nonviral delivery of nucleic acids presents an opportunity to circumvent the 
problems associated with viral vectors. Nonviral vectors are simple to use, can be 
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produced in a large scale and do not cause immune response [4]. They also allow 
specificity for the desired cells/tissues by incorporation of appropriated moieties in the 
vector formulation [3]. One the other hand, these vectors do not have capabilities to 
overcame the cellular barriers and the immune defense mechanisms as the viruses 
and, as a consequence, they fail to be as effective in transfecting cells as viruses. 
Peptides and dendrimers offer a possibility to compact DNA/RNA for systemic delivery 
[2] but the nonviral systems of election for the delivery of nucleic acids are the ones 
based in the cationic lipids and polymers [9]. 
Following the observation of Alec Bangham that phospholipids in aqueous 
systems can form closed bilayered structures, liposomes evolved from being just an 
object of biophysical research to become one of the election pharmaceutical carriers 
for several practical applications. In the past 20 years, advances in the area resulted in 
the appearance of several liposomal drugs, and of many unique liposomal-based 
biomedical products and technologies. 
Liposomes are spherical, self-assembled structures formed in aqueous 
solutions. They as constituted by one or several concentric lipid bilayers, with an 
aqueous phase in their lumen and in-between their bilayers, and can adopt the shape 
of multilamellar vesicles (consisting in of several concentric bilayers with sizes ranging 
between 500 to 5,000 nm), large unilamellar vesicles (ranging in size from 200 to 800 
nm and formed by a single bilayer) and small unilamellar vesicles (around 100 nm in 
diameter). Liposomes show some attractive biological properties as they are 
biocompatible and capable of entrapping water-soluble molecules in their internal 
water compartment, and water-insoluble compounds in their membrane, protecting 
them from the inactivating effect of external conditions and avoiding undesirable side 
reactions. They provide a unique opportunity to deliver drugs into cells or even to 
individual cellular compartments and their size, charge and surface properties can be 
easily tuned by adding new components to the lipid mixture before liposome 
preparation and by variation of the preparation methods themselves. 
The versatility of liposomes allows them to serve for various finalities, by 
functionalization of their surface with various modifiers (figure 1. (A, B, C, D and E)). 
Modifying their surface by attachment of hydrophilic polymers, with highly flexible 
main chain, results in liposomes with high half-life in circulation, while the 
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incorporation of labels allows for monitoring the fate of liposomes inside an organism 
or cell, and for enhanced diagnostic imaging through the preparation of contrast 
liposomes. Liposomes with targeting functionality can be obtained by grafting specific 
ligands, while the attachment of either antibodies or antigens onto the surface of 
liposomes results in immunoliposomes. The incorporation of positively charged lipids 
or positively charged polymers into the liposome allows the binding of nucleic acids 
and the formation of systems for cell transfection [10]. 
 
 
Figure 1. Evolution of liposomes. A) Early phospholipid liposomes with a water soluble drug (a) 
entrapped into the aqueous liposome interior and a water-insoluble drug (b) incorporated into the 
liposomal membrane. B) Antibody-targeted immunoliposome with antibody covalently coupled (c) to 
reactive lipids of the membrane, or hydrophobically anchored (d) into the liposomal membrane. C) 
Long-circulating liposome grafted with a protective polymer (e) such as PEG, which promotes the 
shielding of the liposome surface from opsonizing proteins (f). D) Long-circulating immunoliposome 
simultaneously bearing both protective polymer and antibody, which can be attached to the liposome 
surface (g) or to the distal end of the grafted polymeric chain (h). E) New-generation liposome with its 
surface modified by attachment of: protective polymer (i) or protective polymer and targeting ligand, 
(e.g. antibodies) (j); diagnostic labels (k); positively charged lipids (l), allowing for the complexation with 
DNA/RNA, (m); stimuli-sensitive lipids (n) or stimuli-sensitive polymers (o); cell-penetrating peptides (p); 
and viral components (q). Additionally to a drug, liposome can be loaded with magnetic particles (r), for 
magnetic targeting, and/or colloidal gold or silver particles (s) for electron microscopy [10]. 
 
To promote liposomal drug delivery in specific tissues and organs, targeted 
liposomes with surface-attached ligands capable of recognizing and binding to markers 
on the cells of interest have been developed (Figure 1 B). Immunoglobulins and their 
fragments are widely used as targeting moieties and can be attached to liposomes, 
without affecting either the liposomal integrity or the antibody properties, by covalent 
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binding to the liposome surface or by hydrophobic insertion into the liposomal 
membrane after their functionalization in hydrophobic residues [10]. 
One of the disadvantages of using liposomes is their rapid elimination from 
blood by capture by the cells of the reticuloendothelial system. To achieve long 
circulation of liposomes in vivo, different methods have been suggested including the 
coating of the liposome surface with inert biocompatible polymers such as 
polyethylene gylcol (PEG) to form a protective layer over the liposome surface and 
slow down liposome recognition by opsonins and subsequent clearance [11] (Figure 1 
C). The flexibility of the protective polymers allows a relatively small number of 
polymer molecules to create an impermeable layer over the liposome surface. 
Research on PEGylated liposomes has been focused on the attachment of 
removable PEGs so that this coating detaches under the action of local pathological 
conditions, resulting in improved cellular capture of the liposome [10].  
Clinical research showed that the anticancer agent doxorubicin has been 
selective delivered in PEG liposomes for the treatment of solid tumors in patients with 
breast-carcinoma metastases, resulting in improved survival [12-14], and impressive 
results were obtained for its delivery in unresectable hepatocellular carcinoma [15], 
cutaneous T-cell lymphoma [16] and sarcoma [17]. 
Experiments combining the properties of long-circulating liposomes and 
immunoliposomes in one preparation have been performed, by simple co-
immobilization of an antibody and PEG on the surface of the liposomes, but the 
protective polymer can create steric hindrances for the targeting moiety [18, 19]. To 
improve the selectivity of PEG-coated liposomes, it is advantageous to attach the 
targeting ligand to a PEG spacer arm, so that the ligand is extended outside of the 
dense PEG layer, reducing the steric impediment and refining the binding to the target 
(Figure 1. (D)). 
The overexpression of the folate receptors (FR) in a range of tumor cells makes 
tumors targeting via folate-modified liposomes an interesting approach. After studies 
have established the possibility of delivering macromolecules [20] and then liposomes 
[21] into living cells using folate receptor mediated endocytosis, which could bypass 
multidrug resistance, interest in folate-targeted drug delivery by liposomes grew 
rapidly. Daunorubicin and doxorubicin liposomes have been specifically delivered to 
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various tumor cells through folate receptor targeting and demonstrated increased 
cytotoxicity [10]. Recently, the application of folate-modified doxorubicin-loaded 
liposomes for the treatment of acute myeloid leukemia was combined with the 
induction of FR using all-trans retinoic acid [22]. In gene therapy assays, folate-
targeted liposomes have been used for selective delivery of both plasmids [23] and 
antisense oligonucleotides [24] to tumors.  
The liposome-cell interaction may be specific on non-specific (Figure 2.).  
 
 
Figure 2. Liposome-cell interaction. A)  Drug-loaded liposomes absorb specifically (a) or nonspecifically 
(b) to the cell surface. Liposomes also fuse with the cell membrane (c), releasing their contents into the 
cell cytoplasm, or be destabilized, by certain cell membrane components when adsorbed on the surface, 
(d) releasing the carried drug, which can enter the cell via micropinocytosis. Liposome can undergo 
direct or transfer-protein-mediated exchange of lipids with the cell membrane (e) or enter the cell via 
specific or nonspecific endocytosis (f). In the case of endocytosis, a liposome is either degraded after the 
transformation of the endosome into lysosome (g) or the liposome can provoke endosome 
destabilization (h), which results in drug liberation into the cell cytoplasm. B) Liposome modified with 
specific viral components (a) and loaded with a drug can bound specifically to cells (b), provoke 
endocytosis and, by the interaction of its viral components with the inner membrane of the endosome 
(c), promote the drug efflux into the cell cytoplasm (d). [10] 
 
Gene transfer mediated by liposomes have been explored since the mid 70’s 
when their fusogenic capabilities with the cellular membranes were demonstrated [2]. 
Since the first application of cationic liposomes to gene delivery in 1987 [25], these 
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became broadly utilized as nonviral  vectors for gene therapy. Cationic lipid-based 
liposomes are easy to prepare, reasonably cheap and nonimmunogenic [10].  
Some liposomes, with cationic lipids alone, exhibit good transfection efficiency, 
but the normal procedure is to incorporate helper neutral lipid, such as 
dioleoylphosphatidylethanolamine (DOPE) [8] and 1-monooleoyl-rac-glycerol (MO) 
[26], in the lipid formulation, since these non-bilayer-forming lipids facilitate the lipid 
mixing with the endosome membrane, a crucial step in the endosome release process 
[3, 8].  MO is a promising alternative to common helper lipids, as it seems to combine 
positive aspects of both DOPE and cholesterol: tendency to promote inverted non-
lamellar structures similarly to DOPE (although different from the common inverted 
hexagonal structures [Figure 3. (C)]) and the fluidizing effect of cholesterol, which 
increases the fusogenicity of the lipoplexes  [27]. 
 
 
Figure 3. Different types of pDNA/cationic lipid structural organizations: A) inverted non-lamellar 
hexagonal structure characteristic of cationic vesicles containing DOPE at αDOPE ≥ 0.5; B) lamellar 
structural characteristic of cationic vesicles containing αHelper ≤ 0.5; and C) inverted bicontinuous cubic 
structure characteristic of cationic vesicles containing MO at αMO ≥ 0.5. Double-tailed surfactant with 
grey-headgroup represents cationic lipid, double-tailed surfactant with white-headgroup represents 
DOPE and single-tailed surfactant with white-headgroup represents MO. Grey-coloured regions 
represent cationic lipid rich-domains and white-coloured regions represent MO or DOPE rich-domains 
[27]. 
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Cationic liposomes are also used for the specific delivery of antisense 
oligonucleotides to specific tissues and papers on cationic liposome-mediated delivery 
of small interfering RNA have particularly compared intravenous and intraperitoneal 
administration routes in adult mice [28].  
Figure 4 shows an example of cationic liposomes-nucleic acids complexes 
(lipoplexes) formation. 
 
 
Figure 4. Formation of cationic liposomes-ODN (single-strand oligodeoxynucleotides) complexes. A 
and B) Cryo-TEM images showing the effect of ODN addition to cationic liposomes DOTAP/Chol (4:1). A) 
Observation of lipid membranes fusing (arrow) to a condensed multilamellar particle (arrowhead). B) 
Lipoplexes of DOTAP with ODN, at the isoelectric point, is an aggregate of condensed multilamellar 
particles (white arrows), coexisting with a few free liposomes (black arrow). In the right top corner 
DOTAP/Chol (1:1)-ODN lipoplex, charge ratio 1; consisting in a condensed multilamellar particle (black 
arrowheads pointing to incomplete outer bilayers and white arrowhead signaling a lamellar defect due 
to incomplete inner bilayers). Scale bars represent 50 nm. C) Diagram of lipoplex formation. (1) Initially, 
anionic ODN molecules (gray) may coat the cationic membrane of the liposomes. (2) Two liposomes may 
adsorb to each other due to ODN bridging, leading to liposome aggregation. (3) The destabilization 
promoted by partial charge neutralization may cause one membrane to rupture and wrap around 
another. (4) If local ODN concentration is sufficient more membranes may adsorb to produce a 
condensed multilamellar particle with intercalated ODN layers. (Adapted from [29]) 
 
Many of the finer features of these delivery systems and mechanisms remain 
insufficiently understood, and so the studies in this popular field have concentrated on 
structure, function, and structure–activity relationships, on detailed mechanisms of 
liposome-mediated gene delivery and on improved efficiency of transfection. 
For clinical application the following quality-control assays should be applied to 
liposomal formulations:  
A B
C
1
2
3
4
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• Basic characterization of the pH, osmolarity, trapped volume, phospholipid 
concentration, phospholipid/lipid composition, phospholipid/lipid acyl chain 
composition, cholesterol concentration, active compound concentration, residual 
organic solvents and heavy metals, active compound/lipid ratio and proton or ion 
gradient before and after loading. 
• Chemical stability regarding phospholipid hydrolysis, non-esterified fatty acid 
concentration, phospholipid acyl chain and cholesterol autoxidation and active 
compound degradation. 
• Physical characterization of the appearance, vesicle size distribution, electrical 
surface potential and surface pH, ζ-potential, thermotropic behaviour, phase transition 
and phase separation and percentage of free drug. 
•  Microbiological assays of sterility and pyrogenicity (endotoxin level) [10]. 
 
3. Cellular barriers dictate transfection efficiency 
Several anatomical and cellular barriers limit the overall efficiency of gene 
transfer by nonviral methods.  
Barriers such as the epithelial, endothelial cell linings and the extracellular 
matrix surrounding the cells prevent direct access of macromolecules to the target 
cells. Professional phagocytes such as Kupffer cells in the liver and macrophages in the 
spleen promote an effective clearance of DNA-loaded colloidal particles administered 
through blood circulation. Additionally, the existing nucleases of the blood and 
extracellular matrix rapidly degrade free and unprotected nucleic acids following 
systemic administration [3].  
The plasma membrane crossing is considered the most critical and limiting step 
for an efficient DNA/RNA transfection, as nucleic acids cannot pass through cell 
membrane unless their entry is facilitated by the formation transient holes [30], or 
through various active cellular uptake mechanisms such as endocytosis, pinocytosis, or 
phagocytosis [3]. 
Upon uptake by endocytosis, macromolecules captured within the endosomes 
are usually degraded as these vesicles transform into digestive lysosomes unless some 
escape mechanisms is triggered and the maturation process is interrupted. Two escape 
mechanisms have been explored. One consists in the use of membrane active or 
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fusogenic molecules, such as fusion peptides [31], or lipid components with acid-
sensitive moieties and large hydrophobic portions to rupture the endosome 
membrane [32]. The other mechanism is based on building up osmotic pressure within 
the endosome to cause swelling and eventually burst of the endosomal vesicles [33].  
If released from endosomes, DNA molecules in their free form or as complexes 
must make their way through the cytoplasmic matrix, a viscous protein solution, and 
the cytoskeleton network towards the nucleus where transcription takes place. Direct 
intracellular microinjection of naked DNA has shown that the movement by diffusion is 
slow and inefficient, and as a result the induced gene expression levels are very weak 
[34].  
The nuclear envelope represents an important barrier for the entry of DNA. 
This double-membrane has large protein structures called nuclear pore complexes 
which regulate the molecular transport into and from the nucleus. In the case of the 
delivery of RNA, as the enzymatic machinery necessary for its action is in the 
cytoplasm, the nuclear envelope does not represent an obstacle for its transfection.   
Finally, dissociation of DNA-carrier complexes constitutes another limitation for 
transfection. Cationic lipids dissociate from DNA through lipid mixing and exchange 
with host cell lipids, while DNA complexes formed with cationic polymers, such as PEI, 
remain stable after endosome escape [3]. 
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4. Gene silencing through regulatory small RNA delivery as a promising therapeutic 
tool 
The discovery of RNA interference (RNAi) [35-37] and subsequent findings of its 
mechanisms in mammalian cells generated excitement for its possible application for 
therapy of hard-to-cure diseases, including hepatitis C and human immunodeficiency 
virus (HIV).  
This gene silencing phenomenon promoted by small pieces of double stranded 
RNA with sequence homology to certain genes, seems to have originated as a 
mechanism of defense against the insertion of foreign genetic material.  
The RNAi machinery regulates the expression of genes via small hairpin RNAs, 
called microRNAs, processed in the cytoplasm into double stranded small RNAs [38]. 
MicroRNAs normally have only incomplete sequence homology to their targets and 
work by impeding the translation of messenger RNA (mRNA).  
Figure 5 shows the RNA interference mechanism. The siRNA precursors are 
cleaved by Dicer (an RNAse III– like enzyme) into siRNAs (19 to 21 nucleotide double-
stranded RNAs with a 2 to 3 unpaired nucleotide and characteristic 5’ phosphate and 
3’ hydroxyl groups at each end). As the siRNA enter the RNA-induced silencing complex 
(RISC) it becomes activated and one of the siRNA strands (the guide strand) bounds to 
the complex. If the guide strand is homologous to an mRNA sequence, an enzyme 
within the RISC (Argonaute 2), cleaves the mRNA in the center of the homologous 
region. Since the cleaved mRNA is rapidly degraded and the guide strand of the siRNA 
is protected from degradation by the RISC, this mechanism enables the cleavage of 
many mRNAs, hence preventing the production of the protein for which the mRNA 
encodes [6]. 
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Figure 5. RNA interference mechanism [6]. 
 
Contrarily to the initial notion that effective RNAi requires almost complete 
sequence homology throughout the length of the sequence, it now appears that as few 
as 7 contiguous complementary base pairs can direct RNAi mediated silencing [39]. 
RNAi is can be so specific that it has been possible to silence a mutant gene differing by 
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one nucleotide from its wild-type form [6]. For example, it has been possible to silence 
mutant oncogenic ras without affecting wild-type ras in vitro [40]. 
Inhibiting overexpressed oncogenes should block pathways that cancer cells 
depend on. However, in most cases it may be necessary to target pathways at several 
points, or  several pathways [41]. In this regard,  RNAi-mediated interference of several 
key oncogenes or tumor-promoting genes as inhibited the growth and survival of 
tumor cells [6]. 
Intravenous injection of immunoliposome with its surfaces functionalized with 
polyethyleneglycol grafted to transferrin antibodies (to aid in crossing the blood-brain 
barrier) and to the insulin receptor (to aid in crossing into glioma cells), have delivered 
DNA encoding short hairpin RNA into the brains of mice to suppress the growth of 
injected human glioma cells [42].  
Increased resistance to apoptosis is characteristic of cancer cells. This property 
enables them to survive under abnormal growth stimuli and mediates their increased 
resistance to many chemo and radiotherapeutic agents. Hence, understanding 
apoptosis gives several options to induce cancer cell suicide [41].  
RNA interference increases the apoptotic susceptibility of cancer cells by 
inhibiting antiapoptotic genes, such as bcl-2, livin or surviving. In Hela cells, silencing of 
livin  increased the apoptotic rate in response to different proapoptotic stimuli [43].  
Tumors do not grow more than a few mm3 in size without triggering the 
angiogenic process to develop vessels and increment blood supply. This process is not 
fully understood, but it is most likely stimulated when hypoxia in the tumor 
surroundings leads to the expression of response genes, such as vascular endothelial 
growth factor A and placenta growth factor, which specifically stimulate the growth of 
endothelial cells. Still, tumors seem to easily  get around the blockage of one 
angiogenic pathway, and clinical trials of the inhibitory drugs have underperform [41]. 
In spite of this, when tumor cells producing thrombospondin-1 antiangiogenic 
molecule, under the control of a tetracycline promoter, were transfected with siRNA 
anti VEGF, and then injected into nude mice, an 86% reduction of tumor volume was 
observed [44]. 
Another tricky process to deal in cancer therapy is the development metastases 
development. Expression profiling of melanoma variants with low or high metastatic 
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potential, has allowed the identification of the small GTPase RhoC as a potential RNAi 
target to inhibit the formation of metastases [45]. 
Small interfering RNAs have been designed to silence BCR-ABL tyrosine kinase, 
an anomalous protein that results of a characteristic mutation in chronic myelogenous 
leukemia. Its silencing induces death of K562 leukemic cells at comparable levels to 
those induced by the anticancer drug STI 571 [46]. Additionally, silencing the Lyn 
kinase, which forms a signaling complex with BCR-ABL, induces the death of drug-
resistant chronic myelogenous leukemia cells without affecting the viability of the 
control cells [47]. 
               
5. Chronic myeloid leukemia  
Chronic myeloid leukemia occurs in approximately 25% of patients with acute 
lymphoblastic leukemia (ALL) and some its symptoms are weight loss, fever, and 
abdominal fullness but, at least in developed countries, many patients are 
asymptomatic until an abnormal routine blood count leads to a diagnostic work up. 
The clinical sequence of CML is comprised by two stages. Most patients are 
diagnosed in the chronic or stable phase, which is characterized by myeloid cell 
growth, while cellular differentiation and function is largely maintained. After a 
variable length of time the disease evolves to blast crisis, which may resemble an acute 
leukemia of myeloid, lymphoid or undifferentiated phenotype and carries a poor 
prognosis.  
CML was the first malignant disorder in which a reliable association with a 
chromosomal aberration was demonstrated. Philadelphia chromosome (Ph), originally 
described by Nowell and Hungerford in 1960, was originally thought to be a shortened 
chromosome 22 but subsequent research revealed that Ph is the result of a reciprocal 
translocation between chromosomes 9 and 22. This translocation was shown to fuse 
sequences of the ABL gene from chromosome 9 with BCR on chromosome 22, 
generating a chimeric BCR-ABL gene, which was the first demonstration of an 
oncogenic fusion gene. Subsequently, the BCR-ABL protein was shown to exhibit 
constitutive tyrosine kinase activity that was correlated with cellular transformation. 
ABL (also referred to as ABL-1), is a tyrosine kinase involved in multiple cellular 
processes, including DNA repair, integrin signaling, cell cycle regulation, and signal 
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transduction from cell surface receptors. ABL knockout mice exhibit increased 
neonatal lethality and a number of defects, including skeletal malformations, immune 
dysfunction as well as an ill-defined wasting syndrome.  
The kinase activity of BCR-ABL is absolutely required for cellular transformation. 
The result of the enzymatic activity is a multimeric signaling complex interconnected 
mainly by phosphotyrosine dependent interactions, making the BCR-ABL kinase activity 
instrumental to its formation and maintenance. Signaling output from this complex is 
responsible for the activation of multiple pathways, including mitogen activated 
protein kinases that results in apoptosis inhibition, increased proliferation, and a 
perturbation of cellular adhesion to the bone-marrow stroma. There is also evidence 
that BCR-ABL kinase activity affects DNA repair and induces genomic instability by a 
variety of mechanisms.  This complex signal transduction network, operated by BCR-
ABL, offers a number of potential drug targets downstream of the initiating aberration.  
It could be argumented that chronic phase CML would not be a significant 
clinical problem if it did not lead to blastic transformation. Therefore, prevention of 
blast crisis could be defined as the primary therapeutic goal in CML but the 
mechanisms responsible for disease progression in CML are not fully comprehended.  
The fact that BCR-ABL kinase activity is central to its transforming potency has 
been the foundation for the development of imatinib mesylate for therapy of BCR-ABL 
positive leukemias. There is some evidence that targeting the kinase activity may have 
limitations as some biological effects of BCR-ABL, on migration and adhesion, are 
kinase independent. While these effects obviously do not prevent imatinib from 
inducing responses, it is possible that they contribute to the persistence of residual 
illness and hence, to eliminate these cells agents that target the BCR-ABL protein 
rather than its kinase activity would require [48]. 
 
 
 
 
 
 
 
Introduction 
15 
 
6. Objective 
The advent of nanotechnology along the discovery of RNA interference (RNAi), 
as turned the scope of nanomedicine to the development of devices to specifically 
delivery the pharmacological compound (drug or nucleic acids), to certain cells 
involved the disease processes. This approach would enable the use of lower dosages, 
reducing toxicity and the risk of developing resistance to treatment, as compared to 
other chemotherapeutic approaches.  
Gene silencing by siRNA (short interfering RNA) appeared as a novel strategy 
for post-transcriptional gene silencing with enormous therapeutic potential. One 
attractive vehicle to deliver siRNA into target cells are the cationic liposomes because 
of the simplicity of their complexation with siRNAs, good transfection efficiency, 
superior pharmacokinetic properties, and low toxicity and immunogenicity [49]. 
The aim of this thesis was to develop and characterize novel systems for 
therapeutic siRNA delivery based on DODAC/MO liposomes, following previous work 
by our group with monoolein (MO)-based lipoplexes which have validated them as a 
system for plasmid DNA delivery [26, 50, 51] and demonstrated that they possess 
promising features compatible with stable, efficient encapsulation of RNA. 
Furthermore it is intended to stabilize the lipoplexes by incorporation of polyethylene 
glycol lipids on their membranes to increment the half-life [11] and reducing the 
recognition by the mononuclear phagocyte system. Finally, we intended to obtain 
selectivity to the folate receptor expressing (FR+) target cells (a characteristic of 
several cancers including chronic myeloid leukemia (CML)) [52], by coating the 
liposomes surface with folate grafted PEG lipids. 
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II. Materials and Methods  
 
A. Materials 
Dioctadecyldimethylammonium chloride (DODAC) was purchased from Tokyo 
Kasei; 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-2000] ammonium salt (PEG(2000)-PE) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[folate(polyethylene glycol)-2000] ammonium salt (DSPE-
PEG(2000)-Folate) from Avanti Polar Lipids; 1-monooleoyl-rac-glycerol (MO), heparin 
from the porcine intestinal mucosa, Dulbecco's modified eagle's medium (DME 
medium), Antibiotic/mycotic solution, sodium chloride (NaCl), sodium-pyruvate, 
Trizma Base, thiazoyl blue tetrazolium bromide (MTT), chloroform, methanol, 
ribonucleic acid from torula yeast and β-nicotinamide adenine dinucleotide reduced 
disodium salt hydrate (NADH) from Sigma-Aldrich; RiboGreen kit with TE buffer RNase 
free (20x); Lissamine Rhodamine B 1,2-Dihexadecanoyl-sn-Glycero-3-
Phosphoethanolamine Triethylammonium Salt (Rhodamine B DHPE) and Heat-
inactivated Fetal Bovine Serum (FBS) from Invitrogen; Potassium dihydrogen 
phosphate (KH2PO4•3H2O) from Panreac; Dipotassium hydrogen phosphate trihydrate 
(K2HPO4) and ethanol absolute from Merck; RNase Zap from Ambion; L929, MDA-MB-
468 and MDA-MB-435 from ATCC; HBSS from Lonza;  
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B. Methods  
 
1. Liposomes preparation  
 
1.1 Lipid film hydration 
5 mL of DODAC, MO and Polyethylene glycol (DSPE-PEG 2000) solutions were 
prepared at a 20 mM concentration, by diluting correct masses of the first two lipids in 
ethanol and the latter in chloroform, respectively. As for the preparation of the PEG-
Folate 1 mL lipid solution, to obtain the concentration of 0,31mM, the lipid was diluted 
in a mixture of methanol: chloroform (9:1). These solutions were conserved at 4˚C.      
Appropriated volumes of the desired lipid solutions, as to obtain the wanted 
lipid ratios and concentration of liposomes after hydration, were mixed with a fair 
volume of ethanol in a round bottom flask. Then the mixture is evaporated in a 
rotatory evaporator VV Micro Rotary Evaporator (Heidolf), under vacuum and at 30˚C, 
for 10 minutes. This promotes the formation of a homogenous lipid film in the flask. 
Afterwards the film was hydrated, during 10 minutes and at 30˚C, with an 
appropriated volume of ultrapure water, as to obtain the desired concentration. At 
this point, the liposomes are formed but they are multilamellar and very 
heterogeneous in size. This can be attested by the turbidity of the resulting solution. 
To overcome these issues, and obtain unilamellar and homogeneous liposomes, they 
are subjected 5 extrusion cycles. They are compressed with air, through a filter with a 
pore size of 400 nm in the first cycle, and then four times more, through a filter of 100 
nm of pore (Track-Etched Membranes (Nuclepore)), in a pre-heated extruder (Lipex 
Extruder (Northern Lipids)) at 55˚C, to augment their fluidity and facilitate the 
extrusion. The final solution is much clearer.  
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1.2 DODAC/MO (2:1) liposomes with 1, 2 and 5% PEG (1mM) 
1mM liposomes DODAC/MO (2:1) with different percentages of PEG (1, 2 and 
5%) were prepared by hydration of the lipid film with ultrapure water, according to 
previously described method (1.1).  
These liposomes were subject to DLS analysis in order to determine their 
hydrodynamic diameter (in Polystyrene (10x10x45 mm) cells (Sarstedt)) and ζ-potential 
(in folded capillary cells (Malvern)) in a Zetasizer nano ZS (Malvern). 
 
2. Lipoplexes preparation 
To prepare lipoplexes in the determined charge ratios, the proper volume of 
the solution of the intended liposomes (1 mM), diluted to 0,5 mM, was added to the 
100 μL of a RNA solution at 10 μg/mL. The mixture was then subjected to vortex 
stirring, allowed to rest for an hour and then diluted to a final RNA concentration of 1 
μg/mL.    
The RNA solution was prepared, at the chosen concentration, by diluting an 
adequate mass of RNA in a 20 mM phosphate buffer (pH 6,8, 150 mM of NaCl). This 
Buffer was prepared by mixing 51 mL of a 0,2 M aqueous solution of KH2PO4 with 49 
mL of a 0,2 M aqueous solution of K2HPO4, diluting an appropriated mass of NaCl and 
adding ultrapure water, to obtain a final volume of 200 mL. 
 
                    
  
  ⁄  
 
Equation 1. Charge ratio with np the number of moles of positive charge n(DODAC) for liposomes 
without PEG or PEG-Folate and n(DODAC) – n(PEG) for liposomes with the PEG moieties) and nN the 
number of moles of negative charge (n(phosphates) considering  the RNA molecules are composed of 22 
nucleotides)   
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3. Light interactions with matter 
As all the experiments performed on this work are based on light interactions 
with matter, an introduction on the subject is adequate. 
 Einstein demonstrated that light exists as bundles of wave energy called 
photons, with energies corresponding to the frequency of their waves in the bundle. 
The higher the frequency, the greater the energy carried by that bundle [53].  
 
    ⁄  
 
Equation 2. The wave frequency (ν) relation with wavelength (λ), where c it’s the speed of light in the 
vacuum.  
 
 
Figure 6. The electromagnetic wave with its electric and magnetic fields. Adapted from [54] 
 
While propagating through space, light behavior is better described as a wave, 
when interacting with matter it behaves as a particle (photon), in which its energy (E) 
is given by:  
      
 
Equation 3. Photon’s energy relation with its frequency, with h being the Planck constant (6.626×10−34 
J/s) and ν the frequency of the electromagnetic wave (s-1). 
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The electromagnetic radiation is sorted in a spectrum by the frequency of its waves.  
 
 
Figure 7. The electromagnetic spectrum with the classification of the types of electromagnetic radiation. 
Adapted from [54] 
 
3.1 Absorption 
When light goes through an absorbing medium, if the energy of the photons 
matches that required to promote an energetic level transition of the electrons from a 
ground state to a particular excited state, they are absorbed. The absorption 
proprieties of some compounds can be utilized to quantify them, by measuring the 
intensity of a light beam, of a specific wavelength, after and before its interaction with 
the sample. Comparing the intensity of the incident light (I0) with the intensity of the 
transmitted light (I(λ)) it is possible to infer about the absorption capability of the 
medium. 
                 
 
Equation 4. Light absorption comparing the intensity of the incident light (I0) with the intensity of the 
transmitted light (I), where aλ is the absorption coefficient and Ɩ the thickness of the medium.  
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The light, of a determined wavelength, that passes unaltered through the 
medium is designated by transmittance (Tλ) and is given by: 
 
   
  
  
⁄  
 
Equation 5. Transmittance (Tλ) of the medium. 
 
and it is directly related to the absorbance through: 
 
            
 
Equation 6. Relationship between absorbance (Aλ) and transmittance(Tλ)  . 
 
As the concentration is related to the absorbance coefficient (αλ) through: 
 
            
 
Equation 7. Relationship between the concentration (C) and the absorbance coefficient (αλ), where ελ is 
the molar absorption coefficient. 
 
Considering these previous relations, Beer – Lambert law can be attained [55]: 
 
        
 
Equation 8. Absorption of the medium in function of the concentration of absorbent species.   
 
This law only applies for monochromatic radiation. For each wavelength 
radiation, there’s a corresponding absorption coefficient. If there is more than one 
absorbent species the absorption becomes the sum of their absorbances.     
  
Regarding this work, the absorbance measurements were performed in a 
SpectraMax Plus 384 absorbance Plate Reader (Molecular Devices). 
Materials and Methods 
23 
 
3.2 Fluorescence 
After the electronic excitation promoted by the absorption of electromagnetic 
radiation within the molecules, processes of relaxation take place so that the electrons 
can return to the fundamental state and the molecule to stabilize. 
  
 
 
Figure 8. Jabłoński diagram displaying the formation of a molecular excited singlet state trough 
absorption (ABS), and its decay processes, including fluorescence (FL), phosphorescence (PH), internal 
conversion (IC), intersystem crossing (ISC), vibrational relaxation (VR) and collisional quenching (CQ) 
[56]. 
 
The relaxation processes can be radiative or non-radiative. The latter include: i) 
vibrational relaxation, where the surplus of energy is dissipated (in the form of heat) 
though collisions between the excited molecules and the solvent molecules; ii) internal 
conversion, where transfer of the excited electrons happens between states of equal 
multiplicity; iii) Intersystem crossing, where transfer of the excited electrons arises 
between states of different multiplicity; [57] and iv) collisional quenching, where 
transfer of the excited electrons ensues to a quencher species trough collision. 
The radiative decay processes are the phosphorescence and fluorescence. 
While phosphorescence occurs through transitions from states of different multiplicity 
(from a triplet to a singlet state), with spin-forbidden moves, in fluorescence, the 
transition is spin-allowed and always occurs from the first excited singlet to the 
fundamental state [58]. 
Materials and Methods 
24 
 
 In the fluorescence decay process the fluorescence emission maximum is 
observed at a longer wavelength than the absorption maximum. This energy difference 
between the absorption maximum and the emission maximum is designated as the 
Stokes shift and it’s a result of the loss of vibrational energy in the excited state before 
emission of the photon [59] 
 
 
Figure 9. Representation of the Stokes shift exhibiting the energy difference between the absorption 
maximum and the emission maximum. Adapted from [59]. 
 
Fluorescence can be characterized by several parameters, of which some of 
the most important are the fluorescence intensity at a given wavelength (IF), the 
fluorescence spectrum (emission intensity variation with the emission wavelength), 
the fluorescence quantum yield (φF), the fluorescence lifetime (tF) and polarization 
[56]. 
 
The fluorescence measurements were performed in a Jobin Yvon Fluorolog-3 
(Horiba) spectrofluorimeter in disposable Polystyrene (10x10x45 mm) cells (Sarstedt)) 
and in a Fluoroskan ACEN FL Microplate Fluorometer/ Luminometer (Thermo 
scientific). 
 
 
 
 
 
 
Materials and Methods 
25 
 
3.3 Dynamic light scattering 
 
3.3.1 Size 
Particles, emulsions and molecules in suspension undergo Brownian motion 
[60] (random movement). This motion is induced by the collision with solvent 
molecules that are moving due to their thermal energy or, in other words, by the 
spontaneous diffusion towards a homogeneous distribution in a liquid. This diffusion 
(D) is compared to a well understood reference process: the free diffusion of a single 
particle in a liquid, distant from other particles or a barrier, for which the diffusion 
coefficient (D) is given by: 
  
   
 ⁄  
 
Equation 9.  Einstein’s equation with kB being the Boltzmann's constant (1.38 × 10-23 m
2
.kg.s
-2
.K
-1
), T the 
absolute temperature and f the friction coefficient of the particle . 
 
 In the simplest case, a spherical particle with in a Newtonian fluid (fluid with a 
proportional viscosity to the flow velocity), the friction coefficient for translational 
motion is given by: 
       
 
Equation 10. Stokes friction factor, where η is the viscosity and r the radius of the particle. 
 
The combination of these equations results in: 
 
  
   
    ⁄  
 
Equation 11. Stokes-Einstein equation, for diffusion of spherical particles through liquid with low 
Reynolds number (ratio of inertial to viscous forces). 
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The intensity of the scattered light fluctuates with time at a rate that is 
dependent upon the size of the particles: the smaller the particles are, the more 
rapidly they move. Analysis of these intensity fluctuations yields the velocity of the 
Brownian motion and hence the particle size distribution using the Stokes-Einstein 
equation.  
Other parameters produced by dynamic light scattering are the Z-average size 
and the polydispersity (PDI). The Z-average parameter accounts for the mean 
hydrodynamic radius of the particles and is obtained of the scattered light fluctuations 
through: 
                         
 
Equation 12. Polynomial fit to the log of the of the scattered light fluctuation in time 
 
The value of b is known as the z-average diffusion coefficient and is converted to a size 
using the dispersant viscosity and some instrumental constants. The analysis of the 
intensity of scattered light only gives two values, a mean value for the size, and a width 
parameter known as the Polydispersity. If the distribution is very broad, or rephrasing, 
if the polydispersity is too high (superior to 0,5) the z-average value is unreliable and 
the distribution analysis should be used [61]. 
 
3.3.2 ζ-potential 
The charge at the particles surface affects the distribution of ions in the 
surrounding interfacial region. As a result, an increased concentration of counter ions 
(ions of opposite charge to that of the particle) gathers close to the surface, and an 
electrical double layer forms around each particle. The closer layer to the particle 
surface is called the Stern layer, and their ions are strongly bound. Contiguously to the 
Stern layer there’s a diffuse layer, with its ions less firmly attached, where exists a 
theoretical boundary within which the ions and particles form a stable entity. When 
the particle moves, ions within the boundary move with it, but the ions beyond it do 
not. This boundary is called the surface of hydrodynamic shear or slipping plane. The 
potential that exists at this boundary is known as the ζ-potential [61]. 
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When a charged particle in a gas or liquid is under the influence of a uniform 
electric field, it will be accelerated until it reaches a constant drift velocity according 
to: 
     
 
Equation 13. Drift velocity (v) equation where E is the magnitude of the applied electric field and μ the 
mobility of the particle. 
 
Reformulating, the electrical mobility of the particle is defined as the ratio of the drift 
velocity to the magnitude of the electric field: 
 
    ⁄  
 
Equation 14. Rearrangement of the equation X. 
 
The electrophoretic mobility of a spherical colloidal particle carrying low zeta (ζ) 
potential moving in an electrolyte solution is given by: 
 
  
          
 ⁄  
 
Equation 15.  Henry’s equation, where εr is the relative permittivity, ε0 is the is the permittivity of a 
vacuum, f(kr) is the Henry’s function and η is the viscosity of the electrolyte solution [62].   
 
Henry’s function (f(kr)) is a function used in the theoretical treatment of the 
electrophoretic mobility that accounts on the radius of the macromolecule (r) and its 
reciprocal ion-atmosphere radius (κ). When the limit of kr tends to infinity f(kr) tends 
to 1 and the equation becomes: 
 
  
     
 ⁄  
 
Equation 16.  Marian Smoluchowski equation [62]. 
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When the limit of kr tends 0 f(kr) tends to 2/3 and the takes the form of: 
 
  
        
  ⁄  
 
Equation 17.  Hückel’s equation [62]. 
 
Hence, measuring the electrophoretic mobility through the analysis of the 
intensity fluctuations of scattered light, it is possible to convert the signal into ζ-
potential, through the presented theoretical considerations. 
 
The Dynamic Light Scattering (DLS) measurements were performed in Zetasizer 
Nano ZS (Malvern) placing 1 mL of the intended solution in a disposable Polystyrene 
(10x10x45 mm) cells (Sarstedt)) for the determination of the hydrodynamic diameter 
and 800 μL in folded capillary cells (Malvern) for the determination of the ζ-potential. 
The measurement was made with appropriated SOPs at 25ºC. 
 
4. Liposome stability 
Liposomes DODAC/MO (2:1) and DODAC/MO (2:1) 5% PEG, were prepared at a 
concentration of 1 mM by hydration of the lipid film with ultrapure water, in 
agreement to the method described in 1.1.  
Afterwards, the liposomes were diluted to a final lipid concentration of 100 μM, 
in appropriated volumes of saline, serum, aqueous solutions at pH 3 and 5 and 
ultrapure water (to obtain the conditions pH≈6 and 0 mM NaCl).   
The saline solutions were prepared in ultrapure water, at such concentrations 
that after the addition of the liposomes the final concentrations of NaCl were 5, 10, 50, 
100 and 150 mM. The same was done for the serum solutions, which were diluted, in 
ultrapure water, as to be at 30 and 80% (v/v) after the addition of liposomes.  
The acidified aliquots of ultrapure water (pH 3 and 5) were obtained by titration 
with HCl solutions (0,5 mM and 10 μM) and for pH 5 solution, the final pH was 
adjusted with the addition of NaOH solutions (0,5 mM and 10 μM).  
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These preparations were then subject to dynamic light scattering studies to 
determine the salt and pH effect on the size and ζ-potential and the serum effect on 
the size of the lipid particles in a Zetasizer nano ZS (Malvern). 
 
5. Complexation assays 
Liposomes DODAC/MO (2:1) and DODAC/MO (2:1) 5% PEG (1mM), prepared by 
hydration of the lipid film with ultrapure water as described in 1.1, were diluted to 0,5 
mM, with ultrapure water and used to prepare lipoplexes at charge ratios 0,5; 1; 2; 4; 
6; 8; 10; 15; 20; 25 and 30. This lipoplexes were obtained according to the method 
described in section 2. 
These lipoplexes were subjected to dynamic light scattering analysis, to 
determine their hydrodynamic diameter (in Polystyrene (10x10x45 mm) cells 
(Sarstedt)) and ζ-potential (in folded capillary cells (Malvern)) in a Zetasizer nano ZS 
(Malvern), and to RiboGreen assay, to follow the complexation of the RNA with the 
liposomes as RiboGreen is a RNA intercalating probe that fluoresces when in the RNA 
midst. The RiboGreen assay was conducted, considering manufacturer specifications, 
by plating 100 μL of lipoplexes in a 96 well plate and ultrapure water (for blank) and 
adding 100 μL of RiboGreen (200x). Also, a calibration curve was made, according to 
the manufacture, to assure linearity between the RiboGreen fluorescence and the RNA 
concentration. Briefly, 100 μL of RNA solutions, in phosphate buffer, of 0,04; 0,2; 1 and 
2 μg/mL concentrations with 100 μL of RiboGreen (200x)  were plated to obtain the 
final RNA concentrations of 0,02; 0,1; 0,5 and 1 μg/mL.     
The mixtures were allowed to incubate during 5 minutes and then fluorescence 
was measured in a Fluoroskan ACEN FL Microplate Fluorometer and Luminometer 
(Thermo scientific), using the excitation/emission filter pair of 485/538 nm. 
RiboGreen solution was prepared by 200x dilution of the RiboGreen stock 
solution (750 mM) in 10 mM Tris-HCl, 1 mM EDTA, pH 7,5 (TE) buffer, diluted 20 fold, 
from the stock solution with ultrapure water RNase free. 
This procedure was carried on ice and the utilized micropipettes and gloves 
were cleaned with RNAse zap cleansing solution and RNAse free tips were used.  
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6. Encapsulation efficiency 
To determine the encapsulation efficiency of the lipoplexes at charge ratio 10, 
prepared with Liposomes DODAC/MO (2:1) and DODAC/MO (2:1) 5% PEG as described 
before, were centrifuged, 15 minutes, at 1000 G in 50 KDa amicons (Millipore) 
(Centrifuge 5804 R (Eppendorf)).  These falcon-like tubes have a filter unit, which 
allows the separation of the liposome – RNA complexes of the free RNA. While the 
lipoplexes are retained in the filter unit, the free RNA molecules are small enough to 
pass through the filter. 
After centrifugation, 100 μL of the free RNA fractions and of a RNA solution of 1 
μg/mL (corresponding to the initial concentration of RNA after their dilution to the 
final volume) were plated, in a 96 well plate, along with 100 μL of RNA solutions, in 
phosphate buffer, of 0,04; 0,2; 1 and 2 μg/mL concentrations, to obtaining a 
calibration curve . Then 100 μL of RiboGreen (200 x), prepared in the same fashion as 
described previously, were added to each well and the mixture was allowed to 
incubate for 5 minutes. Also a blank, consisting in a mixture of 100 μL of ultrapure 
water and 100 μL of RiboGreen (200 x), was made. Finally the fluorescence was 
measured in Fluoroskan ACEN FL Microplate Fluorometer and Luminometer (Thermo 
scientific), using the excitation/emission filter pair of 485/538 nm. 
 
7. Lipoplexes stability 
Once again lipoplexes DODAC/MO (2:1) 5% PEG – RNA at C. R. 10 were 
prepared as described previously and diluted to final RNA concentration of 1 μg/mL, in 
appropriated volumes of saline, serum, aqueous solutions at pH 3 and 5 and ultrapure 
water (to obtain the conditions pH≈6 and 0 mM NaCl). 
As in the case of the liposome stability studies, the saline solutions were 
prepared, in ultrapure water, at such concentrations that, after the addition of the 
lipoplexes the final concentrations of NaCl were 5, 10, 50, 100 and 150 mM. The same 
was done for the serum solutions, which were diluted, in ultrapure water, as to be at 
30 and 80% (v/v) after the addition of lipoplexes.  
The acidified aliquots of ultrapure water (pH 3 and 5) were obtained by titration 
with HCl solutions (0,5 mM and 10 μM) and for pH 5 solution, the final pH was 
adjusted with the addition of NaOH solutions (0,5 mM and 10 μM).  
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These preparations were then subject of dynamic light scattering studies to 
determine the salt and pH effect on the size and ζ-potential and the serum effect on 
the size of the lipid particles in a Zetasizer nano ZS (Malvern). 
 
8. Destabilization of lipoplexes 
Lipoplexes DODAC/MO (2:1) and DODAC/MO (2:1) 5% PEG – RNA C. R. 10 were 
prepared as described in 2, with a difference in the in the dilution to obtain the final 
volume. In this case lipoplexes C. R. 10 were diluted by adding the appropriate 
volumes of heparin from the porcine intestinal mucosa (0,121 mM) (a polysaccharide 
with a high negative charge density), as to form 5; 2,5 and 0,5 charge ratios. The final 
volume of 1000 μL was completed with the addition of ultrapure water and the 
solutions were subjected to vortex agitation. 
 As for the previous experiments with RiboGreen, 100 μL of each solution and of 
a RNA solution of 1 μg/mL (corresponding to the initial concentration of RNA after 
their dilution to the final volume) were plated, in a 96 well plate, along with 100 μL of 
RNA solutions, in phosphate buffer, of 0,04; 0,2; 1 and 2 μg/mL concentrations, to 
obtaining a calibration curve . Then 100 μL of RiboGreen (200 x), prepared in the same 
fashion as described previously, were added to each well and the mixture was allowed 
to incubate for 5 minutes. Also a blanks, consisting in a mixture of 100 μL of ultrapure 
water and of a solution of heparin with the same concentration used to obtain the 
charge ratio 0,5 with 100 μL of RiboGreen (200 x), were made. Finally the fluorescence 
was measured in Fluoroskan ACEN FL Microplate Fluorometer and Luminometer 
(Thermo scientific), using the excitation/emission filter pair of 485/538 nm. 
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9. Cytotoxicity assays 
 
9.1 LDH (Lactate dehydrogenase) assay 
This technique allows an indirect measurement of cell viability, since LDH is 
released to the extracellular medium by cells with compromised membranes. LDH 
catalyzes the interconversion of pyruvate and lactate, with NADH oxidation 
(Nicotinamide adenine dinucleotide) or NAD+ reduction acting as reaction catalyst.  
The LDH enzymatic kinetic can be monitored by measuring the absorbance variation at 
340 nm, due to the oxidation of the NADH. As the quantities of NADH and pyruvate are 
a constant in the experimental reaction, the LDH quantity in the extracellular medium 
will determine the slope of the enzymatic kinetic curve.   
 
9.2 MTT assay 
This method involves the conversion of MTT (3,(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) into formazan crystals. When cells are viable, this 
tetrazolium salt is metabolized by mitochondrial enzymes, forming insoluble colored 
crystals that absorb light at a wavelength of 570 nm. If the cellular metabolism 
somehow becomes impaired, formation of formazan crystal will be blocked and, as 
consequence, the absorption of light will be inferior. Thus, measuring the absorption 
of the formed crystals, allows the estimation of cell viability [63] 
 
9.3 Liposomes toxicity 
Liposomes DODAC/MO (2:1) and DODAC/MO (2:1) with 1, 2 and 5% of PEG 
were prepared, at 3 mM lipid concentration, by hydration of lipid film with ultrapure 
water, as described in 1.1.  
L929 cells (cell line of adherent fibroblasts of subcutaneous connective tissue of 
Mus musculus (mouse)) were cultured in DME medium supplemented with 10% (v/v) 
of heated inactivated FBS and 1% (v/v) of antibiotic/antimycotic solution and in an 
atmosphere of 5% CO2 and 37˚C.  
When the cells reached the exponential phase of growth they were seeded, at 
a ratio of 30000 cells per well, in 24 well plates and left overnight, for adhesion, in an 
atmosphere of 5% CO2 and 37˚C.  
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In the following day, the prepared liposomes were sterilized by filtration 
through a membrane filter with a pore diameter of 200 nm (Filtropur S 0,2 (Sarstedt)), 
and diluted in DME medium to a 100 μg/mL concentration.  These solutions were then 
used to prepare the 25 and 5 μg/mL concentrations by preforming the dilutions in 
appropriated volumes of DME medium. The cells’ medium was aspirated and they 
were incubated, in duplicates, with 500 μL of each liposome formulation at 5, 25, 100 
μg/mL concentrations. As control conditions were included cell viability control (adding 
500 mL of fresh DME medium), cell death control (DMSO diluted at 30% (v/v) in DME 
medium) and water control (approximately the same volume of water used to dilute 
the liposomes to a concentration of 100 μg/mL in DME medium). The work with the 
cells was conducted in asepsis within the confinement of a laminar flux chamber Bio II 
A (Telstar).  
After 48 and 72h of incubation of the L929 cell line, extracellular LDH and MTT 
toxicity assays were conducted using the cell medium and the adherent cells 
respectively. The supernatant medium of each well was transferred to eppendorfs and 
centrifuged for one minute at 13000 rpm in a Centrifuge 5418 R (Eppendorf) to 
sediment cells or cellular debris in suspension. After centrifugation, 40 μL of the 
supernatant medium of each condition were placed in a 96 well plate. 250 μL of a 0,31 
mM NADH solution were added, followed by 10 μL of 8,96 mM pyruvate solution in 
phosphate buffer (0,05M, pH 7,4). The measurement of the LDH enzymatic activity was 
made immediately after the addiction of pyruvate, at 30˚C, in a SpectraMax Plus 384 
absorbance Plate Reader (Molecular Devices) using the appropriated software (SOFT 
Max Pro) protocol.  
For the MTT assay, 500 μL of a MTT (10x) (Stock solution of 5 mg/mL) in DME 
medium solution were added to the adherent cells in the wells and left to incubate for 
two hours in an humidified incubator at 37˚C, with 5% CO2. The supernatant medium 
was then carefully aspirated and 500 μL of a DMSO/Ethanol [1:1 (v/v)] solution was 
added to each well. The plate was shaken to dissolve the formazan crystals, after 
which 150 μL of each well, as well as 150 μL of DMSO/Ethanol [1:1 (v/v)] (as blank), 
were transferred into a reading 96 well plate.  The measurement was made in a 
SpectraMax Plus 384 absorbance Plate Reader (Molecular Devices) using the 
appropriated software (SOFT Max Pro) protocol. 
Materials and Methods 
34 
 
9.4 Lipoplex toxicity   
L929 and MDA-MB-468 (adherent epithelial adenocarcinoma cells of the 
mammary gland of Homo sapiens (human), known to express folate receptor α) cell 
lines were cultured in DME medium supplemented with 10% (v/v) of heated 
inactivated FBS and 1% (v/v) of antibiotic/antimycotic solution and in an atmosphere 
of 5% CO2 and 37˚C. After the exponential phase of growth was achieved, the cells 
were plated at a density of  30000 cells per well in 24 well plates for the L929 cell line, 
and at 41700 cells per well for MDA-MB-468 cell line, and left overnight for cellular 
adhesion, in an atmosphere of 5% CO2 and 37˚C. 
Liposomes at 1 mM lipid concentration, prepared by lipid film hydration with 
ultrapure water (as described in section 1.1), were diluted with ultrapure water to a 
final lipid concentration of 0,5 mM and a 10 μg/mL solution of RNA in phosphate 
buffer was prepared. These solutions were filter sterilized using a 200 nm pore sterile 
filter (filtropur S 0,2 (Sarstedt)) in a laminar flux chamber Bio II A (Telstar). 
Appropriated volumes were then mixed to form C.R. 10 lipoplexes (in the same 
manner as described in section 2). After the rest period, the lipoplexes were diluted in 
DME medium to obtain 5, 25 and 100 μg/mL, and the controls were prepared by 
diluting appropriated quantities of DMSO (to 30% v/v), water and RNA (to the 
quantities adjusted for 100 μg/mL of lipid condition) in the referred mediums. Then, 
the ulture medium was aspirated and cells were incubated with 500 μL of each 
solution, of fresh medium (cell viability control) and of a solution of DMSO at 30% (v/v) 
in DME medium (cell death control) in duplicate. An additional  control was prepared, 
also in duplicate, by adding 500 μL of a DME medium solution with a quantity of water 
similar o that of the 100 μg/mL lipid concentration. After 48 and 72h of incubation on 
the L929 and MDA-MB-468 cell lines, extracellular LDH and MTT toxicity assays were 
conducted. The supernatant medium of each well was extracted to eppendorfs and 
centrifuged for one minute at 13000 rpm in a Centrifuge 5418 R (Eppendorf) to cells or 
cellular fragments in suspension. Meanwhile, 500 μL of a MTT (10x) (Stock solution of 
5 mg/mL) in DME medium solution were added to the wells, and subsequently the 
plates were incubated for two hours in an humidified incubator at 37˚C,  with 5% CO2. 
After centrifugation, 40 μL of the supernatant medium of each condition were plated 
in a 96 well plate. 250 μL of a 0,31 mM NADH solution were added, followed by 10 μL 
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of 8,96 mM pyruvate solution in phosphate buffer (0,05M, pH 7,4)solution. The 
measurement of the LDH enzymatic activity was made immediately after the addiction 
of pyruvate, at 30˚C, in a SpectraMax Plus 384 absorbance Plate Reader (Molecular 
Devices)as described.  
After the two hour incubation period, the supernatant medium was carefully 
aspirated and 500 μL of a DMSO/Ethanol [1:1 (v/v)] solution were added to the wells. 
The plate was shaken to dissolve the formazan crystals and 150 μL of each condition, 
as well as 150n μL of DMSO/Ethanol [1:1 (v/v)] (for blank), were placed in a 96 well 
plate.  Absorbance values were assessed as described.    
 
10. Internalization assay 
Rhodamine B DHPE fluorescent labeled DODAC/MO (2:1) 5% PEG and 
DODAC/MO (2:1) 4% PEG 1% PEG-Folate were prepared at 0,5 mM by lipid film 
hydration with  ultrapure water (according to 1.1). The fluorescent probe was 
incorporated to the liposomes by adding an appropriated volume (to obtain a ratio of 
1 molecule of fluorescent probe to 200 of lipid) of a 5x10-5 M ethanolic rhodamine B 
DHPE solution to the lipid mixture that undergone evaporation. 
MDA-MB-468 (folate receptor α positive cells) and MDA-MB-435 (adherent 
spindle shaped ductal carcinoma cells of mammary gland of Homo sapiens (human), 
folate receptor α negative cells) cells were cultured DME medium supplemented with 
10% (v/v) of heated inactivated FBS and 1% (v/v) of antibiotic/antimycotic solution and 
in an atmosphere of 5% CO2 and 37˚C. After reaching the exponential phase of growth 
the MDA-MB-468 cells were plated at an approximately 41700 cells per well and the 
MDA-MB-435 cells at 27800 cells per well density, in 24 well plates and left overnight 
for cellular adhesion, in an atmosphere of 5% CO2 and 37˚C. These seeding cell 
densities had been previously optimized by our research group. 
The rhodamine labeled liposomes were utilized to prepare lipoplexes, at a 
charge ratio of 10, by direct addition to a RNA solution of 10 μg/mL concentration just 
before adding the lipoplexes to the cells. To do so, the liposome and RNA solutions 
were sterilized by filtration through a 200 nm pore filter in aseptic conditions. The 
lipoplexes were left to rest for one hour after which the cells were incubated with the 
sterile DODAC/MO (2:1) 5% PEG and DODAC/MO (2:1) 4% PEG 1% PEG-Folate 
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liposomes, at 40 μg/mL, and their lipoplexes counterparts at 25 and 40 μg/mL lipid 
concentration. These concentrations were obtained by diluting the liposomes and 
lipoplexes in appropriated volumes of HBSS folate free medium. After having made 
these dilutions and aspirated the DME, 500 μL of each condition were added to the 
cells, in duplicates, and a double control was made by adding 500 μL of HBSS medium 
to the cells. 
After six hours of incubation, the extracellular medium was aspirated from the 
wells, the cells were washed one time with 500 μL of PBS 1x to remove any medium 
and extracellular fluorescence traces. After washing, by gently shaking the plate, the 
PBS was aspirated and the cells were lysed adding 500 μL of Tris buffer (10 mM) and 
scratching the bottom of the wells with the pipette tip. The lysates were then 
aspirated and stored in eppendorfs in the dark.   
Immediately after their collection, 450 μL of each lysate were diluted with Tris 
buffer (10 mM) to a final volume of 2000 μL in Polystyrene (10x10x45 mm) cells 
(Sarstedt) and a blank was prepared with 2000 μL of the Buffer. The lysates and blank 
fluorescence was measured in a Jobin Yvon Fluorolog-3 (Horiba) spectrofluorimeter 
excitating at 560 nm and collecting the emission spectrum between 570 and 700 nm. 
To estimate the concentration of liposomes and lipoplexes, calibration curves 
of the fluorescence emission spectrum area versus the concentration, in lipid, of the 
liposomes and lipoplexes were constructed. To do so, liposomes DODAC/MO (2:1) 5% 
PEG and DODAC/MO (2:1) 4% PEG 1% PEG-Folate and the respective lipoplexes charge 
ratio 10 were diluted in appropriated volumes of Tris buffer (10mM) as to obtain the 
lipid concentration of 10 μg/mL (stock solutions). The remaining curve concentrations 
(0,5; 1; 1,5; 2 and 5 μg/mL) were obtained by appropriated dilutions in Tris buffer (10 
mM). Also blanks were made to each concentration by adding the same volume of 
ultrapure water, as that of the liposomes and lipoplexes, to appropriate amounts of 
Tris buffer (10 mM). 
The concentration of internalized lipid were obtained through the calibration 
curves slopes and multiplying the produced values by the dilution factor. 
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10.1 Internalization assay statistics 
Several assumptions were met prior to data analysis. All data were tested for 
normality (Kolmogorov-Smirnov test) and homogeneity of variance (Levene’s test). In 
cases of non-normality and heteroscedasticity, data were square root-transformed 
before parametric analysis. A three-level nested design ANOVA was conducted: the 
“system” was considered to be nested in “cell line” and the “concentration of 
incubation (μg/mL)” was considered to be nested in both. Post hoc comparisons were 
conducted using Student-Newman-Keuls (SNK). A P value of 0.05 was used for 
significance testing. Analyses were performed in STATISTICA (v7). 
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III. Results and Discussion   
 
1. Characterization of liposomes DODAC/MO (2:1) at different PEG percentages 
The main goal of this work was the physico-chemical characterization of stable 
lipoplexes based on the cationic lipid DODAC (dodecil dimetil ammonium chloride) and 
the helper lipid MO (Monoolein) at (2:1) molar ratio, while studying their capacity of 
RNA complexation and release.  In order to improve their stability in blood, targeting 
efficiency and uptake by cells, the inclusion of polyethyleneglycol (PEG) moieties and 
PEG-Folate was included in the formulation with the purpose of optimizing the MO-
based vectors for the delivery of siRNAs specific for a particular molecular target. 
Based on previous work by the research group that showed that DODAB/MO 
based lipoplexes can efficiently condense and transfect cells [50, 64]  together with the 
knowledge that DODAC liposomes were smaller and form more homogeneous vesicles 
compared to DODAB liposomes [65, 66] we decided to use  liposomes composed of 
DODAC and MO to condense siRNA. 
Due to the predominance of DODAC, which tends to form rigid lamellar 
structures, liposomes in this DODAC/MO 2:1 ratio are predominantly lamellar [65, 66]. 
On the other hand, the cubic structures, preferred by MO, contribute to the system’s 
fluidity and enable more accentuated curvatures, which facilitate lipid packing. This 
allowed us to obtain a system with stable lamellar structures while avoiding excessive 
rigidity, presenting constant mean diameters between 120 and 140 nm, low 
polydispersity (≈0,1) and high ζ-potential (close to 60 mV). 
To stabilize and achieve long circulation of liposomes in vivo the coating of the 
liposome surface with inert biocompatible polymers, such as polyethylene glycol have 
been suggested [11]. 
Hence, liposomes consisting of DODAC/MO (2:1) with absence, 1, 2 and 5% of 
PEG were prepared, as to evaluate the effect of the PEG moiety on the system, by lipid 
film hydration followed by extrusion to obtain unilamelar liposomes with well-
controlled sizes and geometries [66, 67]. 
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1.1 Liposomal mean sizes  
Dynamic light scattering (DLS) assays were conducted in order to characterize 
the liposomes and determine their size and ζ-potential, and stability along time. 
 
 
Figure 10. A: Mean diameter; B: Polydispersity and C: ζ-potential of liposomes DODAC/MO (2:1) with 
absence, 1, 2 and 5% of PEG in their composition, 1 day and 1 and 2 weeks after preparation. 
 
 Figure 10. (A) shows that, at one day after preparation, all liposomes prepared 
have small hydrodynamic radius and their mean diameter decreases with the 
increment of PEG percentage. This  feature could be due to the fact of the head of the 
PEG lipid conjugate, by being rather large, has a large hydration sphere which 
increases the curvature promoting a tighter packing of the lipids, resulting in smaller 
liposomes. The same tendency can be observed one and two weeks after preparation, 
except for the formulations with 5 and 1% of PEG, respectively, where the mean 
diameter appears to increase. 
 At all studied time points, the liposomes formulations show low polydispersity 
(oscillating on values close to 0,1) and the formulation containing  5% of PEG showed 
always the lowest values  in all systems. This suggests that the liposomes have a fairly 
uniform size distribution. One and two weeks after preparation there are two 
exceptions to the stated: the polydispersity of the liposomes containing 5 or 1% of PEG 
display higher PDI values (slightly superior to 0,2),  which may reflect some residual 
aggregation of the liposomes (Figure 10. (B)).  
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1.2 ζ-potential of the liposomes 
 In terms of the ζ-potential, we could observe a negative correlation with the 
increment of the PEG percentage of the liposomes (Figure 10. (C)). This correlation 
must be the result of the masking of the positive charge of the DODAC lipids by the 
large headgroup of the PEG lipids. This information combined with the fact that PEG 
contributes with negative charges in the surface of the liposomes, leads to a decrease 
in the potential difference between the Stern and diffuse layers, resulting in the 
reduction of the ζ-potential.  
 It has to be noted that, contrarily to what is verified for the liposomes without 
PEG, which remain stable along time, the ζ-potential of the PEG-inclusive liposomes 
decreases with time (from values of 60 and 50 mV to values ranging around 40 mV). 
The slight increase on polydispersity index observed for the PEGylated liposomes may 
reflect some level of vesicle aggregation that could explain the residual decrease in 
zeta potential over time. 
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2. Cytotoxicity of liposomes DODAC/MO (2:1) at different PEG percentages in L929 
cell line 
The next, natural step was to evaluate the cytotoxicity induced by the different 
liposomal formulations, in order to determine if the presence of PEG promotes, as it 
should, the biocompatibility of the vesicles.  
To do so L929 cell line (mouse cell line routinely used for validation of 
biocompatibility of materials and particles) was used, two assays were performed: the 
LDH extracellular enzymatic activity   assay (which is an assay that infers about cellular 
membrane integrity) and the MTT assay (a method to monitor for metabolic viability), 
and two independent experiments were conducted. The results are displayed as the 
mean of the two independent tests, with duplicates. 
 
 
Figure 11. (A) Membrane integrity, extracellular LDH enzymatic activity cytotoxicity assay and (B) Cell 
viability MTT cytotoxicity assay, (1) 48 hours and (2) 72 hours of liposome incubation, at 5, 25 and 100 
μg/mL in lipid concentration, in L929 cell line. 
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The extracellular LDH activity recorded is of low values, comparable to those of 
the viability control, for the 5 and 25 μg/mL concentrations of all liposomes at both 
time points which indicates low toxicity at these concentrations. In contrast, for 100 
μg/mL liposome concentration, one can see high values of LDH activity for liposomes 
with absence or 1% of PEG at 48 and 72 hours of incubation and as well for liposomes 
with 2% of PEG at later time point. This indicates a protective effect of PEG 
incorporation into the liposome formulation, with the liposomes containing 5% of PEG 
showing the extracellular LDH activity values best indicative of biocompatibility.  
Regarding the MTT assay results, it is clear that the increment of liposome 
concentration correlates with a significant reduction in cellular viability, at the studied 
concentrations, at 48 and 72 hours. There is a clear tendency of higher 
biocompatibility for the liposomes with increasing PEG percentage in their 
composition. This tendency is visible for all systems, at the concentrations tested and 
both time points, except for the liposomes prepared with 1% of PEG, which seem to 
cause more cytotoxicity than liposomes prepared without PEG. 
 This increment of biocompatibility with the increase of PEG in the formulation 
of the liposomes could be due to the already mentioned masking of the positive 
charge promoted by the large headgroup of the PEG lipids (positive charge associated 
with high toxicity accounts [68]).  
 It has to be noted that preparing the liposomes at a higher concentration 
(3mM) allows dilution in a smaller volume of culture medium and hence the water 
does not reduce cellular viability in a substantial manner, as shown by the respective 
control.    
Taking together all these results, liposomes with 5% of PEG have shown to be 
smallest and the most biocompatible, in terms of cell survival, and seem to be very 
stable despite their lower ζ-potential, which should diminish their capability to 
condensate RNA due to the lower superficial charge. These experimental observations, 
together with previous reports by other authors [10, 69], have led us to choose 5% PEG 
liposomes, as the preferred vectors, to continue the work by determine their stability 
in salt, serum and pH, comparing to the behavior of liposomes without PEG. These 
conditions simulate the environment that vesicles encounter after intravenous 
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application (up to 150 mM of salt concentration and 70% of serum of the blood) and 
entering cells trough endocytosis (pH 5 and lower if the endosome is not disrupted). 
 
3. Stability of Liposomes DODAC/MO (2:1) and DODAC/MO (2:1) 5% PEG 
 
3.1 Effect of NaCl concentration on the mean size and ζ-potential  
Previous results have demonstrated that the vesicle size [66] and zeta potential 
of DODAX liposomes are very sensitive to ionic strength (results not shown) so it is very 
important to study the stability of our formulations DODAC/MO/5%PEG at different 
salt concentrations. 
 
 
Figure 12. (1) Mean diameter, (2) polydispersity and (3) ζ-potential of liposomes DODAC/MO (2:1) and 
DODAC/MO (2:1) 5% PEG 1 mM, diluted to 100 μM in solution of different concentration of NaCl (A) at 
the day and (B) one week after incubation. 
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From these results (Figure 12. (A1 and B1)), one can note a diminution of the 
mean diameter of the liposomes DODAC/MO (2:1) without and with 5% of PEG with 
the increment of salt concentration and that the polydispersity is low at all tested 
concentrations (Figure 12. (A2 and B2)). The ionic strength increasing in the liposomes 
vicinity promotes a change in osmotic pressure across their membrane which, by being 
resistant to ions, makes water loss the only possibility for equilibrium restoration [70]. 
The water loss would promote a tighter packing of the liposome membranes and the 
reduction of their size, until a certain extent of packaging is reached, were the lipids 
are so tightly packed that the water outflow stops and so do the liposome shrinking. 
In terms of the ζ-potential, we can observe a slight decrease with increasing 
salinity. This happens with the two types of liposomes, after one day and one week of 
incubation, and could be explained by the alteration on the difference of potential 
between the stern and the diffuse layers. The presence of increasing amounts of salt in 
the diffuse layer may cause the increase in positive charges in the liposomes which 
attracts more anions from the diffuse layer to the stern layer as the concentration of 
salt raises. This causes the reduction in both the superficial charge of the liposomes 
and, by consequence, the ζ-potential. Another observation that can be drawn from 
these results is that the ζ-potential of the liposomes DODAC/MO (2:1) 5% PEG always 
decreased from the day of preparation up to one week after incubation. This is a sign 
of residual aggregation, as stated before, supported by the increase in the 
polydispersity index.  
According to these results the liposomes should be stable in the physiologic salt 
concentrations of blood. 
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3.2 Stability in fetal bovine serum 
The resistance of the liposomes to serum was tested by monitoring the change 
in size of the liposomes formulations upon incubation with two different 
concentrations of serum. 
 
 
Figure 13. Stability of liposomes DODAC/MO (2:1) and DODAC/MO (2:1) 5% PEG 1mM, diluted to 100 
μM in (A) 30 and (B) 80% of fetal bovine serum at 0, 3, 6 and 24 hours. (1) polydispersity and (2) mean 
diameter obtained by calculating of the weighted mean of the all populations. 
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 As it can be observed (Figure 13. (A1 and B1)), the polydispersity for the serum alone 
and the liposomes, with and without PEG, in both serum percentages, is very high (PDI 
values superior to 0,5) for all time points. For these cases, it is not adequate to rely on 
the mean diameter and the calculation of the weighted mean, which accounts for the 
relative percentage of each population, to obtain the mean diameter of the particles 
will provide more reliable data. 
 
     ∑(
         
   ⁄ ) 
 
Equation 18. Weighted mean (W.M.) size of the particle populations (PKx) considering their relative 
percentages (PKx %) 
 
For the serum alone, at a 30% (v/v) dilution with water (Figure 13. (A2)), it is 
visible a weighted mean diameter variation between 140 and 160 nm, whereas at a 
80% (v/v) dilution weighted mean diameter varies between 155 and 170 nm (Figure 
13. (B2)). As serum is constituted of a variety of proteins, most likely with charged 
amino acids residues, most likely with charged amino acids residues, it is expectable 
that aggregates of these proteins drawn together by electrostatic attractions become 
evident (albumin is an example of a serum component with well-known capability of 
interacting with cationic liposomes [71]). The results show that with 80% of serum the 
aggregates are bigger than those seen in 30% of serum. One can also verify that the 
weighted mean diameter of these aggregates is pretty constant along the time points 
studied.  
When the liposomes are added to the serum a considerable quantity of 
proteins may adhere to the liposomes increasing their size [72]. This could explain why 
the weighted mean diameter of the DODAC/MO (2:1) liposomes, at 0, 3 and 6 hours, 
has values close to 200 nm, in 30%, and 220 nm, in 80% of serum, whereas in water 
their mean diameter is around 130 nm.  
 In the case of DODAC/MO (2:1) 5% PEG liposomes, for the same time points, 
their weighted mean diameter takes values between 150 and 160 nm, in 30% of 
serum, and about 170 nm in 80%, when their size in water is close to 100 nm.  Being 
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initially smaller, it is normal that in serum the DODAC/MO/PEG liposomes form 
aggregates of smaller dimensions that those of formed with the liposomes DODAC/MO 
(2:1). The presence of PEG should also impair the aggregation of the proteins to the 
surface of these liposomes, since it reduces their superficial charge, augments the 
hydration in the surrounding environment of the liposomes, and provides steric 
shielding to the protein aggregation. 
In terms of stability, one can infer that both types of liposomes, with and 
without PEG, are stable, up to 6 hours, at 30 and 80 % of serum, once there are no 
appreciable changes in their weighted mean diameter in the 3 first time points. At 24 
hours of incubation in 30 and 80% of serum, the liposomes DODAC/MO (2:1) seem to 
form aggregates of 720 and 310 nm, whereas the liposomes with 5% of PEG form 
aggregate of 490 and 590 nm respectively. This, along with the fact that the solutions 
of the liposomes became cloudy at this last time point, suggests that the liposomes 
became unstable and formed very large complexes with the proteins.         
The results of the incubation of DODAC/MO (2:1) and DODAC/MO (2:1) 5% PEG 
liposomes in saline and serum solutions suggest that they should be stable, after 
intravenous injection, up to 6 hours in the blood stream. 
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3.3 Stability in different pH 
 Figure 14 shows the results of dynamic light scattering of liposomes 
DODAC/MO and DODAC/MO 5% PEG incubated in aqueous solutions at different pHs.  
 
 
Figure 14. (A) mean diameter, (B) polydispersity and (C) ζ-potential of liposomes DODAC/MO (2:1) and 
DODAC/MO (2:1) 5% PEG 1 mM, diluted to 100 μM in water at different pH. 
 
In terms of size, the liposomes, with and without PEG, seem to became smaller 
with the reduction of pH (Figure 14. (A)). This may be due to the increasing 
concentration of cations in the liposomes vicinity promoting an osmotic pressure 
across the liposomal membrane. Since the liposomal membrane is impermeable to 
ions, water is lost from the liposomes so the equilibrium is restored, promoting a 
tighter packing of the liposome membranes and a slight reduction of their size (at a 
certain extent the packaging of the lipids is so tight that stops the water flow and the 
liposome shrinking). In terms of the polydispersity (Figure 14. (B)), the DODAC/MO 
(2:1) and DODAC/MO (2:1) 5% PEG liposomes show low values that do not vary with 
the reduction of pH. 
Regarding the ζ-potential, for DODAC/MO (2:1) liposomes a particular trend is 
not observed upon pH reduction, with values fluctuating between 63 and 50 mV. In the 
case of the DODAC/MO (2:1) 5% PEG liposomes, the ζ-potential decreases form 60 to 
34 mV with the variation of pH from 6 to 5, then stabilizing at pH 3. The water 
acidification could enhance its ionization and the resulting hydroxide ions could be 
attracted by the positive charge of the liposomes, from the diffuse to the Stern layer 
which would result in the reduction of the superficial charge of the liposomes and, by 
consequence, the ζ-potential.   
In summary, the two types of liposomes seem stable in a pH environment 
similar to that of the endosomes, something that would suggest that they won’t 
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became neither unstable nor destabilized the endosome. As a consequence, any load 
that they might carry will probably not be released to the cytosol.  
 
4. Dynamics of RNA complexation  
 
4.1 Dynamic Light scattering studies. 
To study how the produced liposomes complex RNA, DLS experiments were 
performed to follow the changes in mean diameter and ζ-potential at a defined 
[ammonium group] (+)/ [phosphate group](-) charge ratio.  RiboGreen fluorescence 
was also used to quantify the amount of unbound, free RNA upon increment of the 
lipoplexes charge ratio.  
 
 
Figure 15. (1) Mean diameter, (2) polydispersity and (3) ζ-potential of lipoplexes, at increasing charge 
ratios, prepared by addition of liposomes DODAC/MO (2:1) and DODAC/MO (2:1) 5% PEG to a RNA 
solution at 10 μg/mL. 
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 For the lipoplexes prepared with DODAC/MO (2:1) liposomes between the 
charge ratios of 0,5 and 4, the mean diameters observed reach very high values (Figure 
15. (A1)). At low charge ratios, the lipoplexes must consist in an agglomerate of 
liposomes supported by the electrostatic attraction of their positive charges to the 
negative charge of the phosphate groups of the RNA. At charge ratio 0,5, the quantity 
of positive charge in the liposomes is insufficient to neutralize all the negative charges, 
and the lipoplexes are probably aggregates of liposomes surrounded of adsorbed and 
free RNA.  
At charge ratio 1, a neutralization of the (+) and (-) charge occurs. At this charge 
ratio there is sufficient amount of positive charge to complex all RNA and the 
aggregates reach their maximum size. After this point the RNA is condensed. At charge 
ratio 2 and above, there will be an excess of liposomes which will promote, through 
fusion processes, the reorganization of the aggregates and the incorporation of the 
RNA in vesicles that start to get smaller as the charge ratio increases.  
Polydispersity reaches its highest values at charge ratios 1 and 2 (Figure 15. 
(A2)), pointing to a variety of particles resulting of different stages of organization. At 
charge ratio 4, the polydispersity starts to diminish up to a minimum at charge ratio 8, 
which may signify that the lipoplexes are reaching a stable structure. 
In what concerns the ζ-potential of the lipoplexes prepared with DODAC/MO 
(2:1) liposomes, at charge ratios 0,5, 1 and 2, this parameter takes negative values 
slightly below -20 mV, which indicates the presence of free RNA and/or at the surface 
of the aggregates (Figure 15. (A3)).  
At charge ratio 4, the ζ-potential of the lipoplexes gets positive (around 40 mV), 
which would imply the incorporation of the RNA into the particle, and at charge rate 8, 
the ζ-potential values seem to stabilize around values of +50 mV, which could indicate 
the stabilization of the lipoplex structure.  
Knowing that the ζ-potential of the liposomes used to prepare these lipoplexes 
is approximately 60 mV, this means that the lipoplexes have less positive charge at the 
surface and hence that there are still possibly RNA molecules exposed at the outer 
surface of the lipoplexes or pointing to a stratified structure, where some of the 
positive charge lay within the lipoplexes. 
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Comparing the DLS results of the complexation process of RNA by the 
DODAC/MO (2:1) liposomes in the absence or presence of 5% PEG, it is possible to see 
significant differences.  
The presence of PEG seems to impede the formation of large complexes since 
for charge ratios between 0,5 and 4, the size of the lipoplexes is increased to a 
maximum size of only ≈ 125 nm, while for higher charge ratios the lipoplex size is 
smaller (Figure 15. (B1)). This is very likely to result from the steric impediment of the 
large head groups of the PEG lipid conjugates avoiding the formation of large 
agglomerates. Another fact that must be considered for the non-formation of large 
agglomerates is that the electrostatic interactions between the positive charges of the 
liposomes and negative charges of the RNA, that sustain the large aggregates, are 
reduced by the PEG heads, that mask some of the positive charge at the liposome 
surface. Also, the low values of polydispersity of these lipoplexes show that the 
presence of PEG does not allow a heterogeneous distribution of the particle size, 
which supports the notion that RNA complexation by PEG-containing liposomes is 
more homogenous and consistent.       
Similarly, the ζ-potential of the lipoplexes prepared with DODAC/MO (2:1) 5% 
PEG liposomes present negative values at the lowest tested charge ratios. In these 
lipoplexes, only the charge ratios 0,5 and 1 display negative values, -20 and -15 mV 
respectively, which indicates the presence of free RNA and/or adsorbed at the surface 
of the complexes (Figure 15. (B3)). For the DODAC/MO (2:1) 5% PEG lipoplexes 
prepared at charge ratio 2, a positive ζ-potential (≈ 5 mV) was observed and the 
transition from negative to positive values of ζ-potential seems less abrupt than that of 
the DODAC/MO (2:1) based lipoplexes. This leads one to believe that, at this point, 
these lipoplexes are structurally well formed, as indicated by the peak in ζ-potential, at 
a lower charge ratio. The maximum ζ-potential for the lipoplexes DODAC/MO (2:1) 5% 
PEG – RNA (≈ 7 mV) is considerably lower than the one for the lipoplexes DODAC/MO 
(2:1) – RNA (≈ 50 mV) which is expected, considering the liposomes with PEG also have 
lower ζ-potential . That said, once again the ζ-potential of the liposomes is higher (in 
this case considerably) than the resulting lipoplexes the same thought process applies.  
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4.2 RiboGreen assay 
 To better understand the RNA complexation processes, the RNA intercalation 
probe RiboGreen was used. This probe, in the presence of free RNA in solution, 
intercalates between the paired bases and it changes its fluorescence intensity, giving 
an idea of how much free RNA is present at each charge ratio.  
 
 
Figure 16. (A) calibration curve of the fluorescent intensity of RiboGreen in function of RNA 
concentration and (B) complexation of RNA, given by the fluorescent intensity of RiboGreen, in function 
of the charge ratio.  
 
The calibration curve shows a good linearity between the RiboGreen 
fluorescence and the RNA concentration.  
 
                        
 
Equation 19. Calibration curve equation and coefficient of determination of the fluorescent intensity of 
the RiboGreen in function of the RNA concentration. 
 
The RiboGreen assays show that in terms of quantity of free RNA at the 
different charge ratios, the complexation of RNA using liposomes with and without 
PEG seem alike, although DLS complexation assays have pointed to a different 
complexation process in terms of structure.  
These assays indicate that the lipoplexes prepared in absence of PEG at charge 
ratios 0,5 and 1 display a lower fluorescence intensity, meaning that more RNA is 
complexed than when PEG is included in the formulations.  
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At charge ratio 2, the complexation processes appear to normalize for both 
systems, since the fluorescence intensity becomes similar and, consequently, so do the 
free RNA quantities.  
For charge ratio above 6, the lipoplexes DODAC/MO (2:1)/5% PEG/RNA appear 
to have slightly higher RNA quantities complexated, and at charge ratio 8, the 
lipoplexes reached the maximum amount of RNA that they can complex.   
For biological applications, we chose the lipoplexes with charge ratio 10 
because, at this point, both types of lipoplexes (with and without PEG) seem to have 
reached the maximum amount of RNA that they can complex. At inferior charge ratios, 
the lipid concentration in the lipoplexes is fairly below the critical micellar 
concentration of the DODAC/MO (2:1) system (≈45 μg/mL), which could render them 
unstable.  
On the other hand, it is inconvenient to use lipoplexes with larger charge ratios, 
because greater amounts of liposomes it would be necessary, which may lead to an 
increase in toxicity. Finally in the literature accounts there aren’t lipoplexes prepared 
at very high charge ratios [73, 74].     
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5. RNA encapsulation efficiency of both lipoplexes at charge ratio 10 
The encapsulation efficiency of the lipoplexes DODAC/MO (2:1) and 
DODAC/MO (2:1) 5% PEG – RNA carge ratio 10 was determined and compared. The 
free RNA was separated from the lipoplexes solution through centrifugation with 
amicon 50 Kda, with an adequate pore size, and quantified using RiboGreen.         
 
 
Figure 17. (A) calibration curve of the fluorescent intensity of RiboGreen in function of RNA 
concentration and (B) encapsulation efficiency percentage (E.E. %) for lipoplexes DODAC/MO (2:1) and 
DODAC/MO 5% PEG – RNA at charge ratio 10. 
 
The calibration curve of the fluorescent intensity of RiboGreen in function of 
the RNA concentration was constructed to quantify the free RNA, separated from the 
both lipoplexes solutions, and the RNA initially used to prepare the lipoplexes, 
adjusted to a similar volume. This step was carried out to confirm the concentration of 
the RNA utilized in the preparation of the lipoplexes which may contain contaminants. 
 
                        
 
Equation 20. Calibration curve equation and coefficient of determination of the fluorescent intensity of 
the RiboGreen in function of the RNA concentration. 
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It was confirmed that the initial RNA concentration is not considerably different 
from the theoretical concentration (0,43 and 0,5 μg/mL respectively). After calculating 
the RNA concentration of the solution initially used for preparation of the lipoplexes 
and that of the unbound RNA, the encapsulation efficiency was calculated.     
 
            (
      
      
⁄     ) 
 
Equation 21. Encapsulation efficiency percentage (E.E. %), comprising the ratio between free RNA 
concentration ([RNA]f) and initial RNA concentration ([RNA]i). 
 
The encapsulation efficiency values obtained are in good agreement with the 
results of the complexation assay with RiboGreen, which indicated a high quantity of 
RNA complexated for both types of lipoplexes at this charge ratio. Since the 
encapsulation efficiency of the lipoplexes DODAC/MO (2:1) 5% PEG – RNA C. R. 10 is 
slightly higher than that for their equivalents without PEG (98,5 and 97,6% 
respectively), this confirms the apparent trend that the lipoplexes with PEG 
complexate slightly superior quantities of RNA.    
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6. Stability of Lipoplexes DODAC/MO (2:1) 5% PEG – RNA Charge ratio 10 
 Having compared the lipoplexes with and without PEG, stability experiments 
were performed with the lipoplexes DODAC/MO (2:1)/5%PEG/RNA C. R. 10, assuming 
that the inclusion of PEG-Folate does not significantly alter their structural behavior. 
Again, these stability experiments had the aim of matching the conditions that the 
lipoplexes should encounter in the blood stream and inside the endosome upon cell 
uptake.  
 
6.1 Stability of lipoplexes with increasing NaCl concentration and incubation time 
Figure 18 (A1 and B1) shows that the lipoplexes appear very stable in increasing 
concentrations of salt. 
 
 
Figure 18. (1) Mean diameter, (2) polydispersity and (3) ζ-potential of lipoplexes DODAC/MO (2:1) 5% 
PEG – RNA C. R. 10, diluted to 52 μM of lipid concentration, in solutions of different NaCl concentrations 
(A) at the day and (B) one week after incubation. 
 
 For both time points tested, their mean diameter, around 100 nm, is relatively 
constant and the polydispersity remains quite low in increasing concentrations of salt 
(Figure 18. (A1; A2; B1 and B2)). Unlike the liposomes, the lipoplexes do not display a 
reduction in size with the increasing salinity of their environment. A tightly packed 
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structure with low quantities of water in their midst would explain why the lipoplexes 
do not shrink with higher osmotic pressure on their surroundings. 
On the other hand, the ζ-potential of the lipoplexes (Figure 18. (A3 and B3)) 
does follow the same decreasing trend with the rise of salt concentration as seen with 
the liposomes. Once again, the presence of increasing quantities of salt in the diffuse 
layer causes the positive charge of the lipoplexes to draw larger amounts of anions, to 
the Stern layer causing their superficial charge and the ζ-potential to diminish. For the 
lipoplexes, having a low positive starting ζ-potential, at 100mM the amount of negative 
charge at the surface of the lipoplexes is enough to make the ζ-potential shift to 
negative values.  
These results show that the lipoplexes are highly stable in concentrations of salt 
up to 150 mM. 
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6.2 Stability in fetal bovine serum 
 As already seen with the liposomes, the polydispersity of the lipoplexes in 
serum is very high, fluctuating between 0,6 and  1 (Figure 19. A1 and B1).  
The weighted mean was used to estimate the particle size, accounting for the relative 
percentage of each population (Figure 19. (A2 and B2)).    
 
 
Figure 19. Stability of lipoplexes DODAC/MO (2:1) 5% PEG – RNA at C. R. 10 diluted to 52 μM of lipid 
concentration in (A) 30 and (B) 80% of fetal bovine serum at 0, 3, 6 and 24 hours. (1) polydispersity and 
(2) mean diameter obtained by calculating of the weighted mean of the all populations.  
 
Contrarily to what was observed for the liposomes, lipoplexes in serum appear 
with a smaller weighted mean diameter compared to their mean diameter in water. 
While in water their mean diameter is about 100 nm, in 30% of serum it ranges from 
70 to 80 nm at 0 and 3 hours and up to 150 nm at 6 hours. Upon incubation in 80% of 
serum, their resulting weighted mean diameter ranges from 80 to 90 nm in the time 
points between 0 and 6 hours. This reduction in size could be explained by the fact 
that at concentrations of salt as those in the fetal bovine serum, the lipoplexes should 
A1
0 3 6 24
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Time (h)
P
o
ly
d
is
p
e
rs
it
y
A2
0 3 6 24
0
75
150
225
275
400
500
650
Serum
Lipoplexes
Time (h)
S
iz
e
 (
n
m
)
B1
0 3 6 24
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Time (h)
P
o
ly
d
is
p
e
rs
it
y
B2
0 3 6 24
0
75
150
225
275
400
500
650
Serum
Lipoplexes
Time (h)
S
iz
e
 (
n
m
)
Results and Discussion 
60 
 
have low negative values of ζ-potential (approximately -5mV), that must destabilize 
the protein agglomerates but does not promote their adhesion to the lipoplexes, 
leading to their reorganization into smaller protein aggregates. In fact, if we compare 
the size of the populations encountered in the DLS analysis of the 
DODAC/MO(2:1)/5%PEG liposomes with those of the resulting lipoplexes, it is possible 
to see, in both serum percentages, that all of them are larger for the liposomes. This 
observation confirms that the lipoplexes destabilize the protein agglomerates and that 
the proteins do not adhere to their surface, staying in solution under the form of small 
aggregates. These smaller particles encountered in the DLS studies of the lipoplexes in 
serum would account for a smaller weighted mean diameter.     
 Regarding their stability in serum, weighted mean diameter of lipoplexes in 
30% of serum does not vary considerably at 0 and 3 hours. At 6 hours, however, their 
weighted mean diameter increases up to 150 nm, which could be the first sign of 
agglomeration. When incubated with 80% of serum, the lipoplexes appear to be stable 
up to 6 hours. In a similar fashion to what was observed with the liposomes, at 24 
hours both lipoplex formulations  show visible agglutination  which reflects in a 
weighted mean diameter in 30 and 80% of serum of 530 and 290 nm respectively, 
confirming the destabilization of the lipoplexes and the formation of bigger complexes. 
Again, as verified for the liposomes, the lipoplexes appear to be stable in 
conditions simulating their application by intravenous injection.           
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6.3 Stability in different pH 
 Figure 20 shows the results of dynamic light scattering of lipoplexes 
DODAC/MO and DODAC/MO 5% PEG charge ratio 10 incubated in aqueous solutions at 
different pHs. 
 
Figure 20. (A) mean diameter, (B) polydispersity and (C) ζ-potential of lipoplexes DODAC/MO (2:1) 5% 
PEG – RNA C. R. 10 diluted to 52 μM of lipid concentration in water at different pH. 
 
Lipoplexes seem fairly stable with the decrease of pH of the aqueous solutions, 
since neither their mean diameter nor ζ-potential varies considerably, maintaining 
values on the order of 100 nm and 6 mV respectively. Their polydispersity does 
increase with pH reduction, but not to values that would imply the destabilization of 
the lipoplexes. 
This would mean that the lipoplexes should remain stable with the acidification 
of the endosome not releasing their content as consequence. 
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6.4 Destabilization with Heparin  
Since the acidification of the endosome is not an apparent factor for the 
destabilization of the lipoplexes, studying the effect of the negative charge of some 
lipids of the endosome on the lipoplexes, became appealing to determine if that would 
render them unstable.  
To do so, we selected heparin, a polysaccharide with a high negative charge 
density as a model proteoglycan, and used RiboGreen to quantify the amount of RNA 
released from the lipoplexes.   
 
Figure 21. (A) Calibration curve of the fluorescent intensity of RiboGreen in function of RNA 
concentration and (B) percentage of released RNA upon destabilization of the lipoplexes with increasing 
quantities of heparin. 
 
As the heparin did not affect RiboGreen fluorescence emission, the RNA was 
quantified using the equation 22: 
 
                        
 
Equantion 22. Calibration curve equation and coefficient of determination of the fluorescent intensity of 
the RiboGreen in function of the RNA concentration. 
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With this experiment it was possible to observe that the heparin was able to 
promote the release of about 40% of the RNA content of both types of lipoplexes.  The 
remaining 60% of RNA must become contained in vesicles resulting of lipid 
reorganization processes. 
These results show that, unlike the acidic pH, the negative charge of some of 
the endosomes lipids could destabilize the lipoplexes and promote the release of some 
of their content. In case the destabilization of the lipoplexes extends to the endosome 
itself, the RNA should be able to reach the cytosol were it could integrate the RISC 
complex and silence their target messenger RNA.    
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7. Toxicity of lipoplexes DODAC/MO (2:1) 5% PEG (0,5 mM)- RNA (10 μg/mL) C. R. 10 
in L929 and MDA-MB-468 cell Lines. 
Cytotoxicity assays were conducted in L929 and MDA-MB-468 (human cell line 
where the internalization assays were to be conducted) to determine the effect of the 
lipoplexes DODAC/MO 5% PEG – RNA C. R. 10 on cell viability. Two independent 
experiments were conducted and the results presented as their mean.   
 
7.1 Toxicity of lipoplexes DODAC/MO (2:1) 5% PEG (0,5 mM)- RNA (10 μg/mL) C. R. 
10 in L929 cell Line. 
 
 
Figure 22. (A) Membrane integrity, extracellular LDH enzymatic activity cytotoxicity assay and (B) Cell 
viability MTT cytotoxicity assay, (1) 48 hours and (2) 72 hours of lipoplex incubation, at 5, 25 and 100 
μg/mL in lipid concentration, in L929 cell line. 
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The results of the extracellular LDH activity show similar values for the 
lipoplexes at 5 and 25 μg/mL concentrations and the viability control at both time 
points. On the other hand, at 100 μg/mL the lipoplexes promote the destabilization of 
the cell membrane and the release of large amounts of LDH to the extracellular 
environment, which results on the elevated values of activity for the enzyme, upon 
addiction of pyruvate, on both time points. 
As for the controls of water and RNA one can observe that free RNA, at the 
same concentration of that in the lipoplexes at 100 μg/mL in lipid concentration,  does 
not distress the membrane integrity, as the values of enzymatic activity are similar to 
those of the viability control either at 48 or 72 hours. On the contrary, an amount of 
water similar to the one incubated for the preparation of the 100 μg/mL concentration 
causes the release of large amounts of LDH form the cells, probably due to osmotic 
choc. 
MTT assay points towards the same line, as the cell viability decreases as the 
concentration of the lipoplexes augments. This assay reports cell viability values 
around 60 and 70% at 5 μg/mL, for the 48 and 72 hours time points respectively, and 
considerable toxicity already at 25 μg/mL since cell viability presents values around 30 
and 15% at 48 and 72 hours, respectively, something that was not observed in the LDH 
assay. At 100 μg/mL of concentration, the cytotoxicity associated with the lipoplexes is 
very high, being the cell viability comparable to that of the death control. These results 
also show, in agreement with the verified for the LDH test, a low toxicity for the RNA as 
opposed to what transpires for the quantity of water utilized to apply 100 μg/mL of 
lipoplexes. As the lipoplexes have to be prepared with liposomes at 0,5 mM, the 
volume of water utilized to obtain the higher tested concentration seems to be 
sufficient to deregulate the osmotic equilibrium of the cells. Therefore, the high 
toxicity verified to the lipoplexes has to be, at least, partially accounted to the effect of 
the solvent.            
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7.2 Toxicity of lipoplexes DODAC/MO (2:1) 5% PEG (0,5 mM)- RNA (10 μg/mL) C. R. 
10 in MDA-MB-468 cell Line. 
 
 
Figure 23. (A) Membrane integrity, extracellular LDH enzymatic activity cytotoxicity assay and (B) Cell 
viability MTT cytotoxicity assay, (1) 48 hours and (2) 72 hours of lipoplex incubation, at 5, 25 and 100 
μg/mL in lipid concentration, in L929 cell line. 
 
Similar conclusion can be drawn for the cytotoxicity studies performed in the 
MDA-MB-468 cell line. The cytotoxicity has to be tested to determine if the lipoplexes 
only show considerable toxicity at the larger concentration tested. The results of cell 
viability show that, in fact, there is a very low toxicity for the lipoplexes at 5 μg/mL and 
at 25 μg/mL in this cell line, with values of cell survival around 100 and 80% 
respectively, for either time point. At 100 μg/mL lipid, although the lipoplexes present 
very high toxicity, at both time points but especially at 72 hours, the results are not as 
accentuated as for the same conditions in the L929 Cell line. Once again the water 
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control promotes very low cell survival numbers, somewhat better to those for the 
L929 cell line, while RNA seems not to distress the cells viability too much.     
When comparing the toxicity results of the MTT assay for both cell lines, 
condition by condition, it seems as the MDA-MB-468 cell line tolerates the lipoplexes 
better.  
8. Internalization Assays 
 The next step on the work was to evaluate the internalization of the lipoplexes 
to understand if there is specificity to the folate receptor. To do so Lipoplexes 
prepared with liposomes DODAC/MO (2:1) 5% PEG and DODAC/MO (2:1) 4% PEG 1% 
PEG-Folate were incubated in the MDA-MB-468 cell line, which expresses the folate 
receptor, and in MDA-MB-435, that does not.  
 To determine the quantity of liposomes and lipoplexes internalized in MDA-
MB-468 and MDA-MB-435 cell line, calibration curves of the fluorescence emission 
spectrum area in function of the lipid concentration of all systems were constructed, as 
to account for the different fluorescent signals, so it would be possible to estimate the 
lipid concentration of the internalized vesicles. The fluorescence emission spectrum 
area was utilized instead of the maximum fluoresce emission, or the fluorescence 
value at the emission wavelength of the rhodamine B DHPE (580 nm), because at the 
quantities of probe used in the experiment, the fluorescence emission is quite low and 
the fluorescence signal has noise fluctuations. Utilizing the area of the fluorescence 
emission peak should dilute the noise fluctuations and produce more reliable results.  
 
 
Figure 24. Calibration curves of the fluorescence emission peak area in function of the lipid 
concentration of liposomes (Lps) and lipoplexes C.R.10 (Lpx) DODAC/MO (2:1) 5% PEG (PEG) and 
DODAC/MO (2:1) 4% PEG 1% PEG-Folate (PEG-Fol) for the (A) first and (B) second assay. 
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The first conclusions that can be withdrawn are that the calibration curves for 
the liposomes and lipoplexes, of both systems, are very similar and that the systems 
comprising PEG-Fol fluoresce less than those only with PEG.  Hereupon it was decided 
that the curves of the liposomes PEG and PEG-Fol were the ones to be used to 
estimate the quantity of liposomes and lipoplexes since they have better coefficients 
of determination. 
 
A1:                         
A2:                         
B1:                         
B2:                         
 
Equations 23. Calibration curve equations and coefficients of determination of the (1) liposomes 
DODAC/MO (2:1) 5% PEG and the (2) liposomes DODAC/MO (2:1) 4% PEG 1% PEG-Folate utilized to 
estimate the quantity of liposomes and lipoplexes internalized in the (A) first and (B) second assays. 
 
Relatively to the experiments of internalization, it has to been mentioned that 
they were initially to be performed only in MDA-MB-468 cell line. Later on it was 
decided to test the systems in a cell line that does not express the folate receptor as 
well, which gave no time to preform toxicity assays on the MDA-MB-435 cell line. Since 
the incubation time is only of 6 hours there is not much toxicity expected, despite the 
incubation of lipoplexes in concentrations of 25 and 40 μg/mL and of liposomes at 40 
μg/mL, so we can assure a measurable fluorescent signal, and the fact of rhodamine 
being  known as a toxic compound. In fact, upon microscopic observation, the cellular 
morphology does not seem altered after the incubation period. 
 
Results and Discussion 
69 
 
 
Figure 25. Quantity of liposomes (Lps), at 40 μg/mL internalized in MDA-MB-468 and MDA-MB-435 cell 
lines (C), and lipoplexes C. R. 10 (Lpx), at 25 and 40 μg/mL, DODAC/MO (2:1) 5% PEG (PEG) and 
DODAC/MO (2:1) 4% PEG 1% PEG-Folate (PEG-Fol), internalized in (A) MDA-MB-468 and (B) MDA-MB-
435 cell lines. Different letters, above error bars, represent significant statistical differences among 
systems.  
 
From the results of these experiments, presented as the mean of the two 
independent assays, it is possible to infer that, for both cell lines, the systems with 
PEG-Folate internalize better than the ones only with PEG (Figure 25.). For the vesicles 
applied to the MDA-MB-468 cell line it is visible that the liposomes show higher 
internalization that their lipoplexes counterparts and that the internalization grows 
with the increasing vesicle concentration, trends that are not clear in the MDA-MB-435 
cell line. Comparison between cell lines indicates that, for all the tested conditions, the 
internalization of the vesicles with PEG-Folate is higher in the MDA-MB-468 cell line, 
while the internalization of the vesicles without PEG-Folate doesn’t seem to vary 
considerably between cell lines. These results suggest that the liposomes and 
lipoplexes without PEG-Folate, not displaying differences between cell lines, should 
enter in the same manner (fusion or, most likely, endocytosis). Conversely, as the 
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vesicles with PEG-Folate internalize better in the MDA-MB-468 cells, one can infer that 
they must enter this cell line by other path, most likely by receptor-mediated 
endocytosis. Overall these results point to the specificity of the PEG-Folate systems for 
the cells folate receptors, as confirmed by the statistical analysis (see figure 25.).          
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IV. Conclusion and future work 
 
The characterization of the liposomes DODAC/MO (2:1) and DODAC/MO (2:1) 
with 5% of PEG has shown that these vesicles are stable in solutions of crescent 
concentrations of salt, in 30 e 80% (v/v) of FBS (up to six hours) and in aqueous 
solutions of different pH. Their mean diameters decrease in saline solutions of crescent 
salt and H3O
+ concentrations, probably as the result of osmotic pressure build up 
across the liposome membranes, which results in water loss from the liposome lumen.  
Liposomes induced cytotoxicity in L929 cell line depending on the lipid 
concentrationand the inclusion of PEG seems to render the vesicles more 
biocompatible.  
The complexation of liposomes DODAC/MO (2:1) and DODAC/MO (2:1) 5% PEG 
with RNA has shown distinct processes, at least in terms of morphology, but that 
resulted in high encapsulation efficiency (at charge ratio 10) for both types of 
lipoplexes. 
Similarly to the observed with the liposomes, both types of lipoplexes are 
stable in solutions of crescent concentrations of salt and H3O
+ but their mean diameter 
does not diminish with the increment of the osmolarity, which would suggest that the 
lipoplexes have a tightly packed structure with low water content. The lipoplexes also 
appear stable in serum solutions of 30% and 80% (v/v), but they were destabilized in 
the presence of heparin, causing the liberation of some of their RNA content. This 
indicates that they may be destabilized by the negatively charged components of the 
endosome membrane and release some of the carried RNA. 
In terms of cytotoxicity, in L929 and MDA-MB-468 cell lines the lipoplexes 
DODAC/MO (2:1) and DODAC/MO (2:1) 5% PEG – RNA charge ratio 10 also lead to lipid 
concentration-dependent toxicity. 
Regarding the internalization, it was possible to infer that, for both cell lines, 
the liposomes and lipoplexes with PEG-Folate internalize better than the ones only 
with PEG, and that the systems with PEG-Folate in their constitution seem to show 
specificity for folate receptor-mediated internalization.   
In the future, cryo-TEM studies should be performed to determine the lipoplexes 
structure. More internalization tests should also be conducted, in other cell lines and 
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resorting to other technics, such as confocal microscopy, so as to obtain definite 
evidence about the selectivity towards the folate receptor, and transfection 
experiments have to be developed to see if the lipoplexes can deliver their load.  
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Appendix 1 
Dynamic light scattering results of a FBS 30% (v/v) solution 
T=0h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
36,13 1 134,2 9,218 3941 78,1 18,9 3 
43,86 0,631 76,3 337,8 7,964 52,5 30,4 17 
43,58 0,63 149,1 8,448 0 81,4 18,6 0 
43,33 0,629 65,3 280,2 7,986 44,9 38 17,1 
43,1 0,624 134,1 8,968 4342 77,1 20,6 2,3 
 
T=3h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
44,17 0,634 85,63 360,1 8,418 55,6 26,5 18 
42,86 0,623 152,2 8,561 0 80,9 19,1 0 
42,8 0,62 149 8,514 4430 79,3 19 1,6 
42,83 0,626 176,3 7,662 0 82,6 17,4 0 
42,57 0,626 143,2 8,654 4738 78,1 20,3 1,6 
 
T=6h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
42,89 0,627 77,53 336 8,18 51,8 30,4 17,9 
42,42 0,618 241,3 51,24 8 46,1 37,6 16,3 
42,35 0,615 174,4 8,018 0 81,5 18,5 0 
42,02 0,613 80,79 383,7 8,013 56,4 25,1 18,6 
42,09 0,623 158,3 9,116 0 79,7 20,3 0 
 
T=24h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
42,74 0,627 82,75 396,5 8,054 55,8 25,8 18,4 
41,78 0,615 72,08 295,2 8,636 48,2 33,2 18,6 
41,47 0,614 189,6 8,549 0 79,8 20,2 0 
41,6 0,617 212,1 48,25 7,722 50,5 32 17,5 
41,54 0,616 178,2 8,086 0 80,6 19,4 0 
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Dynamic light scattering results of a FBS 80% (v/v) solution 
T=0h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
53,21 0,615 82,58 360,3 8,242 49,9 34 16 
39,34 1 247,4 57,43 8,033 51,6 33 15,4 
38,88 1 195,4 8,407 0 82,8 17,2 0 
38,65 1 163,9 7,886 3962 81,1 16,6 2,3 
38,8 1 231,8 47,02 7,576 56,3 29,2 14,5 
 
T=3h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
39,18 1 190 8,498 0 83 17 0 
38,6 1 74,49 312,8 8,137 45,4 38,6 16,1 
47,78 0,676 220 47,42 7,652 56,2 28,9 14,9 
38,25 1 187,5 7,978 0 83,1 16,9 0 
38,4 1 78,81 363,5 7,87 50,9 33,3 15,8 
 
T=6h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
38,97 1 68,32 273,6 7,92 43,3 40,9 15,8 
38,48 1 209,4 8,385 0 82,8 17,2 0 
38,34 1 236,5 57,59 8,315 50 33,5 16,5 
38,24 1 160,3 10,43 4148 77,1 20,8 2,1 
38 1 185,7 8,283 0 82,6 17,4 0 
 
T=24h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
39,29 1 222,4 43,13 8,073 60,6 24,4 15 
38,48 1 86,82 400,4 8,075 53,8 29,8 16,4 
38,05 1 89,16 377,3 8,19 53,4 30 16,7 
38,04 1 190,2 8,287 0 82,7 17,3 0 
37,88 1 179,1 8,576 0 82,1 17,9 0 
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Appendix 2 
Dynamic light scattering results of liposomes DODAC/MO (2:1) in FBS at 30% (v/v) 
T=0h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
129,2 0,359 204,6 0 0 100 0 0 
129,4 0,355 201,6 7,879 34,48 91,3 5,2 3,6 
127,5 0,354 201 0 0 100 0 0 
127,6 0,358 201,9 9,176 25,35 91,5 5,4 3,1 
128,8 0,359 203,5 0 0 100 0 0 
 
T=3h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
120,8 0,475 205,1 7,873 0 94,4 5,6 0 
127,3 0,362 203,5 19,04 5,579 91,3 5,8 2,9 
121,3 0,489 221,4 39,85 0 91,8 8,2 0 
121,3 0,482 199,1 7,81 22,83 91,1 5 3,9 
129 0,365 206,6 8,568 25,54 92,2 5,7 2,1 
 
T=6h Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
119,2 0,558 211,5 9,171 0 94,1 5,9 0 
129,9 0,365 210,9 8,777 36,41 90,8 5,6 3,6 
129,3 0,361 208,8 39,12 0 94,2 5,8 0 
125,2 0,485 212,4 7,954 33,58 90,8 5,1 4,1 
123,8 0,49 222,6 42,26 0 92,8 7,2 0 
 
T=24h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
269,7 0,509 495,4 4418 0 94,4 5,6 0 
267 0,506 276,8 2197 8,26 65,6 29 3,3 
267 0,483 348,2 3934 0 87,2 12,8 0 
261,8 0,558 444,9 5045 0 97,3 2,7 0 
268,3 0,504 441 4646 0 94,2 5,8 0 
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Dynamic light scattering results of liposomes DODAC/MO (2:1) in FBS at 80% (v/v) 
T=0h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
85,67 0,729 260,5 39,96 7,231 75,8 15 9,2 
90,23 0,641 274,5 43,91 7,802 75,2 15,2 9,6 
85,01 0,724 286,9 50,76 7,429 69,3 21,2 9,5 
89,46 0,635 255,7 8,423 0 88,9 11,1 0 
85,71 0,732 287,9 52,17 7,599 70,4 19,8 9,7 
 
T=3h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
82,15 0,716 278,4 51,16 8,092 71,5 17,7 10,8 
82,21 0,721 282,5 53,94 8,125 69,6 19,5 10,9 
87,98 0,644 303,2 51,97 8,322 71 18,4 10,6 
64,46 1 326,1 62,9 9,273 65,4 23,5 11,1 
87,43 0,641 242,6 8,194 4258 86,9 11,3 1,8 
 
T=6h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
80,93 0,717 293,4 59,58 7,9 66,6 22 11,4 
81,81 0,726 334,7 59,36 7,656 63 26,3 10,7 
64,01 1 303,1 45,86 7,733 70,3 19,4 10,3 
82,49 0,737 332,5 56,33 7,735 64,3 25 10,7 
64,6 1 317,3 54,6 7,869 67,5 21,7 10,8 
 
T=24h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
75,04 1 537 71,66 7,85 59,3 29,9 10,8 
75,48 1 470 58,66 7,616 65,2 24,8 10 
80,84 1 358,9 58,22 7,904 62,2 22,4 10,4 
75,42 1 441,6 51,1 7,95 68,1 19,8 10,1 
75,05 1 501,6 60,89 8,025 64,8 25 10,2 
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Dynamic light scattering results of liposomes DODAC/MO (2:1) 5% PEG in FBS at 30% (v/v) 
T=0h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
78,37 0,61 178 22,32 7,438 83,8 8,3 7,9 
78,37 0,604 179 7,663 31,41 83,3 8,9 7,9 
77,85 0,61 185,8 34,77 7,637 80,5 10,6 8,9 
78,57 0,613 178,7 18,66 6,985 84,3 8,8 6,9 
79,36 0,615 180,7 7,419 26,76 84,7 8,6 6,7 
 
T=3h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
73,87 0,613 178,2 7,623 0 90 10 0 
71,27 0,694 195,3 38,04 7,139 76,2 14,4 9,4 
71,16 0,697 190,3 34,33 7,473 78,8 11,3 9,8 
74,7 0,618 189,3 33,63 8,081 79,5 10,3 10,2 
70,66 0,694 200,2 36,32 6,86 74,8 16,4 8,8 
 
T=6h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
73,76 0,621 186,1 7,463 31,46 80,3 10,2 9,5 
75,01 0,634 194,7 28,21 7,722 79,5 11,1 9,3 
74,64 0,632 214,5 40,72 7,711 75 15 10,1 
75,17 0,628 183,1 7,947 0 89,5 10,5 0 
75,17 0,622 190,1 8,001 0 88,9 11,1 0 
 
T=24h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
108,4 1 534,8 89,03 7,377 66,6 23,7 7,6 
107,2 1 630,6 123,7 7,463 57,6 31 7,6 
118,5 1 581,9 89,16 8,738 67 22,4 8,9 
118,1 1 357,2 3826 7,529 83,6 8,7 7,7 
125,4 1 428,5 7,324 4064 78,8 7,4 7 
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Dynamic light scattering results of liposomes DODAC/MO (2:1) 5% PEG in FBS at 80% (v/v) 
T=0h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
70,48 0,639 238,1 48,89 8,22 69,8 17,6 12,6 
66,93 0,719 249,4 50,51 7,701 66 22 12 
70,57 0,641 258,5 54,69 7,895 65,5 22,1 12,4 
66,97 0,72 273,4 63,32 8,133 58,8 28,5 12,8 
65,69 0,704 216,6 7,741 31,98 77,6 11,6 10,8 
 
T=3h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
58,54 0,667 201,6 8,527 0 84,8 15,2 0 
46,65 1 97,2 399,5 9,169 48,6 35,5 15,4 
59,91 0,68 263,6 54,89 7,942 59 27,2 13,9 
59,41 0,674 269,8 54,92 7,827 57,7 28,7 13,6 
46,31 1 232,7 39,63 7,818 69 17,3 13,7 
 
T=6h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
59,16 0,674 325,4 70,27 7,788 47,9 37,8 14,3 
46,65 1 273,6 57,73 8,388 58,2 27,3 14,5 
46,74 1 293,8 62,88 8,41 54 31,4 14,5 
59,81 0,679 268,3 54,38 7,391 58,3 28,4 13,4 
46,35 1 281,2 55,06 7,642 56,8 29,7 13,5 
 
T=24h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
d.nm   d.nm d.nm d.nm % % % 
122,9 1 979,5 71,65 8,284 71,2 20 8,8 
123,2 1 686,1 78,06 8,172 62,4 25,2 9,1 
135,6 1 642,8 73,68 7,893 60,5 25 9,3 
123,7 1 992,6 106,9 11,09 59,4 29,3 11 
124,5 1 1067 75,34 8,392 68,8 22,1 9,1 
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Appendix 3 
Dynamic light scattering results of RNA lipoplexes C. R. 10 in FBS at 30% (v/v) 
T=0h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
r.nm   r.nm r.nm r.nm % % % 
31,13 0,654 92,78 15,42 3,53 74,1 15,9 10 
31,42 0,653 84,54 3,988 0 87,4 12,6 0 
31,25 0,656 83,87 4,258 0 86,7 13,3 0 
31,85 0,669 88,26 5,576 0 84 16 0 
31,23 0,655 84,85 4,136 0 87,3 12,7 0 
 
T=3h 
Z-
Ave 
PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
r.nm   r.nm r.nm r.nm % % % 
30,15 0,649 82,46 4,071 0 86,2 13,8 0 
30,1 0,653 88,27 4,5 0 85,7 14,3 0 
30,52 0,661 91,23 4,258 0 86 14 0 
30,55 0,657 92,78 4,942 0 84,1 15,9 0 
30,59 0,658 93,26 4,048 0 86,6 13,4 0 
 
T=6h 
Z-
Ave 
PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
r.nm   r.nm r.nm r.nm % % % 
35,41 1 248,2 47,93 7,509 52,7 32,6 8,5 
33,91 1 213,2 33,05 4,001 61,8 27,7 10,5 
35,73 1 161,9 4,196 2333 87,2 11,2 1,6 
35,97 1 218,9 38,62 4,75 60,8 26,9 12,3 
33,73 1 181,5 21,34 3,922 73 16,2 9,9 
 
T=24h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
r.nm   r.nm r.nm r.nm % % % 
78,35 1 1209 97,76 19,55 49,7 33,5 10,1 
93,26 0,933 92,53 691,2 2077 45 30,1 17,4 
93,03 0,929 297 35,93 2396 56,5 21,1 13,7 
84,36 0,997 396,4 50,63 2208 48,5 29,7 13 
89,9 0,9 411,6 63,65 2533 44,2 32,1 8,3 
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Dynamic light scattering results of RNA lipoplexes C. R. 10 in FBS at 80% (v/v) 
T=0h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
r.nm   r.nm r.nm r.nm % % % 
28,73 0,659 154,4 35,92 4,279 47,4 37,2 15,4 
28,54 0,656 86,43 4,251 2344 83,4 15,5 1,1 
28,91 0,656 149,2 35,22 4,03 47,6 37,9 14,6 
22,73 1 89,38 3,852 2247 83,9 14,5 1,6 
28,98 0,662 143,5 30,03 3,925 52,9 33,1 14 
 
T=3h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
r.nm   r.nm r.nm r.nm % % % 
20,03 1 84,31 4,076 2221 82 16,6 1,4 
20,13 1 94,05 3,901 0 84,3 15,7 0 
27,43 0,634 149,1 34,75 3,957 45,4 39,6 15 
27,38 0,632 122,7 27,22 3,912 55 30,4 14,6 
27,38 0,633 88,96 4,118 0 83,4 16,6 0 
 
T=6h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
r.nm   r.nm r.nm r.nm % % % 
19,85 1 148,6 34,66 3,854 43,7 41 15,2 
20,02 1 141,8 35,1 3,944 44,4 40,1 15,5 
20,12 1 98,32 4,258 0 83,6 16,4 0 
20,23 1 95,29 4,294 0 83,1 16,9 0 
20,01 1 134,1 30,98 4,01 48,8 35,8 15,4 
 
T=24h 
Z-Ave PdI Pk 1 
Mean Int 
Pk 2 
Mean Int 
Pk 3 
Mean Int 
Pk 1 
Area Int 
Pk 2 
Area Int 
Peak 3 
Area Int 
r.nm   r.nm r.nm r.nm % % % 
44,1 0,856 196,9 34,13 1690 44,9 26,9 15,3 
41,11 0,935 158,9 34,99 1515 39,7 28,1 20 
40,88 0,932 252,8 20,68 3,763 66,6 14,7 10,8 
40,72 0,936 304,2 23,35 4,002 64,9 16,7 11,4 
43,22 0,829 143,5 26,71 1621 52,2 18,9 16,8 
 
 
